Human Anti-il-33 neutralizing monoclonal antibody
Human anti-IL-33 monoclonal antibodies targeting specific continuous amino acid sequences on IL-33 address the challenge of antigenicity and efficacy, providing effective neutralization with reduced immune response.
Patent Information
- Application Number
- JP2024134557
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-04-04
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2034-12-26
AI Technical Summary
Existing anti-IL-33 monoclonal antibodies face challenges in identifying epitopes consisting of continuous amino acid sequences, leading to reduced efficacy and increased antigenicity when administered to humans, due to sequence mutations in the framework region.
Development of human anti-IL-33 monoclonal antibodies that bind to specific continuous amino acid sequences at positions 101-154 or 199-270 of IL-33, with mutations only in the complementarity determining regions, maintaining a human germline framework region to reduce antigenicity and enhance binding efficacy.
The antibodies effectively neutralize IL-33 function, reducing the risk of human anti-human immunoglobulin antibody responses and maintaining therapeutic efficacy while minimizing inflammation.
Smart Images

Figure 2024156980000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a human anti-IL-33 neutralizing monoclonal antibody and an antibody that competes with said antibody, as well as a cytokine expression inhibitor containing said antibody, and a pharmaceutical composition for treating, preventing, or alleviating an IL-33-related disease. [Background technology]
[0002] Interleukin-33 (IL-33) is a cytokine belonging to the interleukin-1 family that is thought to play a role in inflammatory conditions. IL-33 is constitutively expressed in the nuclei of epithelial cells and vascular endothelial cells, and is released upon cell destruction due to tissue injury caused by infection or physical or chemical stress, where it functions as an alarmin. It is also thought that IL-33 expression is increased by stimuli such as lipopolysaccharide, and that there is also a mechanism for secretion. IL-33 released outside the cells can activate intracellular signals by binding to the IL-33 receptor expressed on the cells. The IL-33 receptor is expressed in various immune cells and epithelial cells, and IL-33-induced intracellular signaling occurs in these cells.
[0003] IL-33 is thought to induce allergic inflammation (asthma, atopic dermatitis, hay fever, anaphylactic shock, etc.) by inducing the production of Th2 cytokines (IL-4, IL-5, IL-6, IL-13, etc.) from immune system cells that express the IL-33 receptor, such as Th2 cells, mast cells, eosinophils, basophils, NK (natural killer) T cells, and group 2 innate lymphocytes (Non-Patent Document 1: Tatsukuni Ohno et al., Allergy, 2012, Vol. 67, p. 1203). In addition, in mast cells and macrophages, which are immune cells that express IL-33 receptors, IL-1β, IL-6, and TNF (tumor necrosis factor)-α are induced by IL-33 stimulation, and it has been suggested that this is involved in the development of autoantibody-induced arthritis (a model of rheumatoid arthritis) (Non-Patent Document 2: Damo Xu et al., Journal of Immunology, 2010, Vol. 184, p. 2620). It has been suggested that IL-33 antagonists are effective against acute kidney injury (Non-Patent Document 3: Ali Akcay et al., Journal of American Society Nephrology, 2011, Vol. 22, p. 2057).In humans, increased expression of IL-33 has been observed in various inflammatory diseases (rheumatoid arthritis, asthma, systemic sclerosis, fibrosis such as hepatic fibrosis and pulmonary fibrosis, psoriasis, ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing spondylitis, etc.), and IL-33 is thought to be involved in the onset and maintenance of various diseases (Non-Patent Document 4: Yasushi Matsuyama et al., Journal of Rheumatology, 2010, Vol. 37, p. 18; Non-Patent Document 5: David Pre´fontaine et al., Journal of Allergy and Clinical Immunology, 2010, Vol. 125, p. 752; Non-Patent Document 6: Koichi Yanaba et al., Clinical Rheumatology, 2011, Vol. 30, p. 825; Non-Patent Document 7: AL Rankin et al., Journal of Immunology, 2010, Vol. 184, p1526;Non-patent document 8: Tamar Mchedlidze et al., Immunity, 2013, Vol. 39, p357;Non-patent document 9: Liang-An Hu et al., Asian Pacific Journal of Cancer Prevention, 2013, Vol. 14, p2563;Non-patent document 10: Luca Pastorelli et al., Proceedings of the National Academy of Sciences of the United States of America, 2010, vol. 107, p8017).
[0004] Since the involvement of IL-33 in various diseases, particularly inflammatory diseases, is known, agonists and antagonists of IL-33 have been developed (Patent Documents 1 to 4). In particular, antibodies against IL-33 have attracted attention in terms of their specificity and potency. However, the antibodies developed so far are mouse antibodies with no identified epitope (Patent Document 1), or antibodies that identify the cleavage site of IL-33 by caspase and identify that the active form is uncleaved IL-33 (Patent Document 2) and have an epitope in the region containing the cleavage site (residues 155 to 198 of SEQ ID NO: 226 in the Sequence Listing), based on the identification of the cleavage site and the identification of the active form as uncleaved IL-33, and commercially available goat polyclonal antibodies are known. On January 10, 2014, AnaptysBio reported on its website that it had succeeded in producing ANB020, a therapeutic candidate antibody against IL-33, using its proprietary somatic hypermutation (SHM-XEL) platform (Non-Patent Document 11: Hamza Suria, 'AnaptysBio announces development of novel anti-IL-33 therapeutic antibody', [on line], 2014, [retrieved on 11 January 2014], Retrieved from Internet:<URL: http: / / www.anaptysbio.com / anti-il-33 / > ). Murphy et al. obtained 20 types of human anti-IL-33 monoclonal antibodies using VelocImmune mice, which are mice into which human antibody variable region genes have been introduced (Patent Document 5). However, the epitopes of the antibodies have not been disclosed, and the amino acid sequences of the framework regions of the 20 types of human anti-IL-33 monoclonal antibodies differ from the amino acid sequences of the human germline by two or more amino acid residues. Therefore, when these antibodies are administered to humans, an immune response against the antibodies is induced, and there are problems in that the efficacy is reduced and inflammation and other side effects are induced due to the induction of human anti-human immunoglobulin antibodies (HAHA). [Prior art documents] [Patent documents]
[0005]
Patent Document 1
Patent document 2
Patent document 3
Patent document 4
Patent document 5
Non-licensed literature
[0006] [Non-licensed document 1] Tatsukuni Ohno et al., Allergy, 2012, Vol. 67, p120 [Non-licensed document 2] Damo Xu et al., Journal of Immunology, 2010, Vol. 184, p2620 [Non-licensed document 3] Ali Akcay et al., Journal of American Society Nephrology, 2011, Vol.22, p2057
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
[0007] In recent years, the relationship between IL-33 and diseases has become clear, and anti-IL-33 neutralizing monoclonal antibodies that have antagonistic effects against IL-33 are desired. The action of anti-IL-33 neutralizing monoclonal antibodies is closely related to the region of the epitope to which the antibody binds. Since IL-33 is released outside the cell upon cell destruction, it is highly likely to be cleaved by lysosomal protease or the like, which may result in the so-called mature IL-33 and many fragments derived from the mature IL-33 that have the activity of IL-33. When a fragment contains an epitope consisting of a continuous amino acid sequence, a monoclonal antibody that binds to an epitope consisting of a discontinuous amino acid sequence is advantageous because it binds more strongly to one continuous amino acid sequence of the fragment and inhibits the binding of the fragment to the IL-33 receptor, for example, than a monoclonal antibody that binds to an epitope consisting of a discontinuous amino acid sequence. However, it has remained difficult to identify an epitope consisting of such a continuous amino acid sequence for generating an IL-33 monoclonal antibody having the desired antagonistic activity.
[0008] It is desirable that an anti-IL-33 neutralizing monoclonal antibody that binds to an epitope consisting of a continuous amino acid sequence of IL-33 has low antigenicity when administered to humans, etc. If it is a human antibody, it is desirable that it has low antigenicity when administered to humans, and further that the framework region is a human germline amino acid sequence or a combination thereof. However, when the SHM-XEL platform or the like is applied to a human antibody contained in a human antibody gene library, amino acid sequence mutations occur not only in the complementarity determining region but also in the framework region. In addition, even when a mouse into which a human antibody gene has been introduced is immunized with a human IL-33 protein to obtain a human anti-IL-33 neutralizing monoclonal antibody, it is not possible to prevent the occurrence of amino acid sequence mutations in the framework region of the anti-IL-33 neutralizing monoclonal antibody. Therefore, it has been difficult to obtain an isolated human monoclonal antibody against IL-33 in which the amino acid sequence of the framework region is a human germline amino acid sequence or a combination thereof. [Means for solving the problem]
[0009] As a result of intensive research conducted by the present inventors to solve the above-mentioned problems, they found that while antibodies that strongly bind to the epitope located at positions 155 to 198, which was previously thought to be a preferred epitope, have almost no antagonistic activity, epitopes consisting of a consecutive amino acid sequence located at positions 101 to 154 or 199 to 270, particularly epitopes consisting of a consecutive amino acid sequence located at positions 111 to 130, 131 to 150, 231 to 250, or 251 to 270, are important in terms of the antagonistic activity of antibodies that bind to said epitopes, and thus arrived at the present invention.
[0010] Furthermore, the present inventors isolated a human anti-IL-33 neutralizing monoclonal antibody from a human antibody library, and further identified a complementarity determining region with high binding affinity and good physical properties by introducing mutations only into the complementarity determining region. As a result, a human antibody that does not contain mutations in the amino acid sequence of the germline framework region and that binds to human IL-33 and neutralizes its function was obtained. Thus, the present invention relates to the following inventions:
[0011] [1] A monoclonal antibody that binds to an epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing. [2] The antibody according to item 1, wherein the epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing is an epitope consisting of a consecutive amino acid sequence included in positions 111 to 130, 131 to 150, 231 to 250, or 251 to 270 of SEQ ID NO: 226 in the Sequence Listing. [3] The antibody according to Aspect 1 or 2, wherein the epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing is an epitope consisting of an amino acid sequence including amino acids selected from P118, I119, T120, Y122, L123, R124, S125, L126, S127, Y129, N130, D131, Q132, S133, T135, A137, L138, E139, S142, Y143, E144, I145, Y146, E148, D149, L150, D244, N245, H246, K266, L267, S268, and E269. [4] The antibody according to any one of Items 1 to 3, wherein the epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing is an epitope consisting of a consecutive amino acid sequence included in positions 111 to 130, 131 to 150, 231 to 250, or 251 to 270 of SEQ ID NO: 226 in the Sequence Listing. [5] The antibody according to any one of Items 1 to 4, wherein the epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing is an epitope consisting of a consecutive amino acid sequence included in positions 138 to 147 or 139 to 147 of SEQ ID NO: 226 in the Sequence Listing. [6] The antibody according to any one of Aspects 1 to 5, wherein the monoclonal antibody binds to an epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing, and is an antagonist of IL-33. [7] The antibody according to any one of Aspects 1 to 6, wherein the monoclonal antibody binds to an epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing, and inhibits binding between an IL-33 receptor and IL-33. [8] A pharmaceutical composition for treating, preventing, or alleviating an IL-33-related disease, comprising the antibody according to any one of items 1 to 7. [9] A cytokine expression inhibitor comprising the antibody according to any one of items 1 to 7.
[10] The inhibitor according to item 9, which suppresses expression of TNF-α, IFN-γ, IL-1β, IL-4, IL-5, IL-6 or IL-13.
[11] The inhibitor according to item 9 or 10, which suppresses the expression of IFN-γ, IL-5, IL-6 or IL-13.
[12] 1) The epitope according to any one of items 1 to 5, 2) an epitope consisting of an amino acid sequence in which one or several amino acids are substituted, deleted, or added to a sequence consisting of consecutive amino acids of the epitope; and 3) An epitope consisting of an amino acid sequence having at least 90% sequence identity to a sequence consisting of consecutive amino acids of the epitope. An epitope selected from the group consisting of:
[13] An antibody generated or screened using the epitope described in Item 12.
[14] The antibody according to any one of Items 1 to 7, wherein the monoclonal antibody that binds to an epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing is a chimeric antibody, a humanized antibody, or a human antibody.
[15] The antibody described in Item 14, wherein the amino acid sequence of the framework region is an amino acid sequence of a human germline framework region or a combination thereof.
[16] The amino acid sequence of the light chain framework region 1 is from residue 1 to residue 22 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 2 is from residue 36 to residue 50 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 3 is from residue 58 to residue 89 of SEQ ID NO: 317 in the Sequence Listing, and the amino acid sequence of the light chain framework region 4 is from residue 3 to residue 12 of SEQ ID NO: 401 in the Sequence Listing, and the amino acid sequence of the heavy chain framework region 1 is from residue 1 to residue 22 of SEQ ID NO: 367 in the Sequence Listing. 16. The antibody according to item 15, wherein the amino acid sequence of the heavy chain framework region 2 is residue 36 to residue 49 of SEQ ID NO: 367 in the Sequence Listing or residue 36 to residue 49 of SEQ ID NO: 368 in the Sequence Listing, the amino acid sequence of the heavy chain framework region 3 is residue 67 to residue 98 of SEQ ID NO: 367 in the Sequence Listing or residue 67 to residue 98 of SEQ ID NO: 368 in the Sequence Listing, and the amino acid sequence of the heavy chain framework region 4 is residue 5 to residue 15 of SEQ ID NO: 407 in the Sequence Listing.
[17] The antibody according to item 15 or 16, wherein the amino acid sequence of the light chain framework region 1 is residues 1 to 22 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 2 is residues 36 to 50 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 3 is residues 58 to 89 of SEQ ID NO: 317 in the Sequence Listing, and the amino acid sequence of the light chain framework region 4 is residues 3 to 12 of SEQ ID NO: 401 in the Sequence Listing; and the amino acid sequence of the heavy chain framework region 1 is residues 1 to 30 of SEQ ID NO: 367 in the Sequence Listing, the amino acid sequence of the heavy chain framework region 2 is residues 36 to 49 of SEQ ID NO: 367 in the Sequence Listing, the amino acid sequence of the heavy chain framework region 3 is residues 67 to 98 of SEQ ID NO: 368 in the Sequence Listing, and the amino acid sequence of the heavy chain framework region 4 is residues 5 to 15 of SEQ ID NO: 407 in the Sequence Listing.
[18] An isolated human anti-IL-33 neutralizing monoclonal antibody, in which the combination of amino acid sequences of light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3) is selected from the combinations shown in C1 to C30 in Table 1.
[0012] [Table 1]
[0013]
[19] The human anti-IL-33 neutralizing monoclonal antibody according to Aspect 18, wherein the combination of the amino acid sequences of light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3) is selected from the combinations shown in C1 to C28 of Table 1.
[20] The human anti-IL-33 neutralizing monoclonal antibody according to Aspect 18 or 19, wherein the combination of amino acid sequences of light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3) comprises an amino acid sequence selected from the combinations shown in C1, C8, C15, C17, and C18 in Table 1.
[21] The human anti-IL-33 neutralizing monoclonal antibody according to any one of Aspects 18 to 20, wherein the amino acid sequence of the antibody framework region is the amino acid sequence of a germline framework region or a combination thereof.
[22] The amino acid sequence of the light chain framework region 1 is from residue 1 to residue 22 of SEQ ID NO: 317 in the sequence listing, the amino acid sequence of the light chain framework region 2 is from residue 36 to residue 50 of SEQ ID NO: 317 in the sequence listing, the amino acid sequence of the light chain framework region 3 is from residue 58 to residue 89 of SEQ ID NO: 317 in the sequence listing, and the amino acid sequence of the light chain framework region 4 is from residue 3 to residue 12 of SEQ ID NO: 401 in the sequence listing, and the amino acid sequence of the heavy chain framework region 1 is from residue 1 to residue 30 of SEQ ID NO: 367 in the sequence listing or the sequence 22. The human anti-IL-33 neutralizing monoclonal antibody according to any one of Items 18 to 21, wherein the amino acid sequence of framework region 2 of the heavy chain is residues 36 to 49 of SEQ ID NO: 367 in the Sequence Listing or residues 36 to 49 of SEQ ID NO: 368 in the Sequence Listing, the amino acid sequence of framework region 3 of the heavy chain is residues 67 to 98 of SEQ ID NO: 367 in the Sequence Listing or residues 67 to 98 of SEQ ID NO: 368 in the Sequence Listing, and the amino acid sequence of framework region 4 of the heavy chain is residues 5 to 15 of SEQ ID NO: 407 in the Sequence Listing.
[23] The human anti-IL-33 neutralizing monoclonal antibody according to any of Aspects 18 to 22, wherein a combination of amino acid sequences of the light chain variable region and the heavy chain variable region is selected from the combinations V1 to V30 of Table 2.
[0014] [Table 2]
[0015]
[24] The human anti-IL-33 neutralizing monoclonal antibody according to Aspect 23, wherein the combination of the amino acid sequences of the light chain variable region and the heavy chain variable region is selected from the combinations V1 to V28 of Table 2.
[25] The human anti-IL-33 neutralizing monoclonal antibody according to Aspect 23 or 24, wherein a combination of the amino acid sequences of the light chain variable region and the heavy chain variable region is selected from the combinations shown in Table 2 as V1, V8, V15, V17, and V18.
[26] The human anti-IL-33 neutralizing monoclonal antibody according to any of Aspects 18 to 25, wherein the light chain is a λ chain.
[27] The human anti-IL-33 neutralizing monoclonal antibody according to any one of Aspects 18 to 26, wherein the human anti-IL-33 neutralizing monoclonal antibody is an IgG.
[28] The human anti-IL-33 neutralizing monoclonal antibody according to any of Aspects 18 to 27, wherein the antigen is human IL-33 or monkey IL-33.
[29] A nucleic acid molecule encoding a protein portion of the human anti-IL-33 neutralizing monoclonal antibody according to any one of items 18 to 28.
[30] The nucleic acid molecule according to Item 29, wherein a combination of nucleic acid sequences encoding the amino acid sequences of light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3) is selected from the combinations shown in CN1 to CN30 of Table 3.
[0016] [Table 3]
[0017]
[31] A vector comprising the nucleic acid molecule of item 29 or 30.
[32] A host cell comprising the vector described in item 31.
[33] A method for producing the human anti-IL-33 neutralizing monoclonal antibody according to any one of items 18 to 28, comprising culturing the host cell according to item 32.
[34] A cytokine expression inhibitor comprising the human anti-IL-33 neutralizing monoclonal antibody according to any one of items 18 to 28.
[35] The inhibitor according to item 34, which suppresses expression of TNF-α, IFN-γ, IL-1β, IL-4, IL-5, IL-6 or IL-13.
[36] The inhibitor according to item 34 or 35, which suppresses expression of IFN-γ, IL-5, IL-6, or IL-13.
[37] A pharmaceutical composition comprising the human anti-IL-33 neutralizing monoclonal antibody according to any one of items 18 to 28.
[38] The pharmaceutical composition according to item 37, for use in the prevention, treatment or alleviation of an IL-33-associated disease.
[39] The pharmaceutical composition according to Aspect 38, wherein the IL-33-associated disease is selected from the group consisting of asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, liver fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[40] An anti-IL-33 neutralizing monoclonal antibody whose binding to IL-33 competes with the antibody of item 20 or 25.
[41] A method for treating, preventing, or alleviating an IL-33-associated disease in a patient, the method comprising administering to a subject the antibody described in any one of items 1 to 7 and 18 to 28.
[42] The method according to Aspect 41, wherein the IL-33-associated disease is selected from the group consisting of asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, liver fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[43] Use of the antibody according to any one of items 1 to 7 and 18 to 28 for the manufacture of a medicament for treating, preventing, or alleviating an IL-33-associated disease.
[44] The use according to Aspect 43, wherein the IL-33-associated disease is selected from the group consisting of asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, liver fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[45] Use of the antibody according to any one of items 1 to 7 and 18 to 28 for treating, preventing, or alleviating an IL-33-associated disease.
[46] The use according to Aspect 45, wherein the IL-33-associated disease is selected from the group consisting of asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, liver fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[47] A method for treating, preventing, or alleviating a patient in need of inhibition of cytokine expression, the method comprising administering to the subject an antibody according to any one of items 1 to 7 and 18 to 28.
[48] The method of claim 47, wherein the cytokine is TNF-α, IFN-γ, IL-1β, IL-4, IL-5, IL-6 or IL-13.
[49] Use of the antibody according to any one of items 1 to 7 and 18 to 28 for the manufacture of an agent for suppressing cytokine expression.
[50] The use of item 49, wherein the cytokine is TNF-α, IFN-γ, IL-1β, IL-4, IL-5, IL-6 or IL-13. Effect of the Invention
[0018] The monoclonal antibodies that bind to the epitopes of the present invention bind to epitopes consisting of a continuous amino acid sequence, and therefore are likely to exert a neutralizing effect even when IL-33 is degraded and fragmented by binding strongly to a single continuous amino acid sequence. The monoclonal antibody of the present invention, when administered to humans, is unlikely to induce human anti-human immunoglobulin antibodies (HAHA) against the framework region and / or complementarity determining region of the antibody. If it is not inhibited by HAHA, the effect of neutralizing IL-33 in the body will last. Furthermore, if it does not cause inflammation due to binding to HAHA, it is a safe antibody. Since the monoclonal antibody of the present invention can bind to human IL-33 and neutralize its function, it can be used as a new diagnostic, preventive, therapeutic or alleviating drug for IL-33-related diseases. [Brief description of the drawings]
[0019] [Figure 1] FIG. 1 is a diagram illustrating each domain and cleavage site of the IL-33 protein. [Diagram 2] FIG. 2 shows the binding activity of each antibody to human IL-33 protein (residues 112 to 270) and each partial peptide fragment (PEP11 to 26). [Diagram 3] FIG. 3 is a diagram showing a model of the three-dimensional structure of a complex between mature human IL-33 (residues 117 to 270) (referred to as "S117-T270" in the figure) and human ST2 (hST2). [Figure 4] Figure 4 is a diagram showing only a portion of the PEP12 epitope of human IL-33 (positions 117 to 130 of sequence number 226 in the sequence listing) (referred to as "S117-N130" in the figure, and the same applies below) and human ST2 in the three-dimensional structure modeling of Figure 3. [Diagram 5] FIG. 5 is a diagram showing only the PEP14 epitope of human IL-33 and human ST2 in the three-dimensional structure modeling of FIG. [Figure 6] FIG. 6 is a diagram showing only the PEP24 epitope of human IL-33 and human ST2 in the three-dimensional structure modeling of FIG. [Figure 7] FIG. 7 is a diagram showing only the PEP26 epitope of human IL-33 and human ST2 in the three-dimensional structure modeling of FIG. [Figure 8]FIG. 8 is a graph showing the effect of human anti-IL-33 neutralizing monoclonal antibody A25-3H04 on inflammation induced by intraperitoneal administration of human IL-33, based on inflammation-related indicators (spleen mass, serum IL-5 concentration, blood eosinophil count, blood basophil count, blood neutrophil count, serum IgA concentration, and serum IgE concentration). [Figure 9] FIG. 9 shows the effects of human anti-IL-33 neutralizing monoclonal antibodies A10-1C04, A23-1A05, A25-2C02, and A26-1F02 on inflammation induced by intraperitoneal administration of human IL-33, based on inflammation-related indicators (spleen mass, blood eosinophil count, blood basophil count, blood neutrophil count, serum IgA concentration, and serum IgE concentration). [Figure 10] FIG. 10 is a graph showing the time course of mouse plasma concentration of human anti-IL-33 neutralizing monoclonal antibodies (A23-1A05, A25-3H04, A26-1F02, A10-1C04, A25-2C02). [Figure 11] FIG. 11 is a graph showing the time course of serum concentration of human anti-IL-33 neutralizing monoclonal antibodies (A10-1C04, A23-1A05) in monkeys. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] To facilitate understanding of the present invention, the following describes terms used in the present invention.
[0021] [Epitope] In the present invention, the term "epitope" refers to a portion of an antigen that is recognized by an antibody. In the present invention, the term "epitope" refers to a sequence of consecutive amino acids that is necessary for antibody recognition.
[0022] [Combine] In the present invention, the term "binding" of a monoclonal antibody to an epitope means that the monoclonal antibody binds to the peptide that is the epitope to form a complex. The binding between the monoclonal antibody and the epitope is due to, but not limited to, ionic bonds, hydrogen bonds, hydrophobic bonds, van der Waals forces, etc. Whether the monoclonal antibody binds to the epitope can be examined, for example, by using the peptide array scan or KinExA described herein.
[0023] [antibody] In the present invention, the term "antibody" is used in the broadest sense and includes monoclonal and polyclonal antibodies as long as they exhibit the desired specific binding property. The antibody in the present invention may be an antibody derived from any animal, such as a mouse antibody, a human antibody, a rat antibody, a rabbit antibody, a goat antibody, or a camel antibody.
[0024] [Monoclonal antibodies] Among the antibodies of the present invention, the monoclonal antibody refers to an antibody of an antibody population consisting of only a single clone (single molecular species) in the designed amino acid sequence. The monoclonal antibody includes chimeric antibodies, humanized antibodies, human antibodies, multispecific antibodies, artificial antibodies, functionally modified antibodies thereof, conjugated antibodies thereof, and fragments thereof. The monoclonal antibody of the present invention can be produced by any known method such as the hybridoma method, the phage display method, and genetic engineering methods.
[0025] [Chimeric antibody] A chimeric antibody refers to an antibody in which the light chain, the heavy chain, or both, are composed of a variable region of non-human origin and a constant region of human origin.
[0026] [Humanized antibody] A humanized antibody refers to an antibody that is composed of a variable region consisting of a complementarity determining region of a non-human antibody and a framework region of a human antibody, and a constant region of a human antibody.
[0027] [Human antibody] A human antibody refers to an antibody in which both the light chain and the heavy chain are derived from humans. Depending on the difference in the constant region of the heavy chain, human antibodies include IgG (including IgG1, IgG2, IgG3, and IgG4) having a γ heavy chain, IgM having a μ heavy chain, IgA (including IgA1 and IgA2) having an α heavy chain, IgD having a δ heavy chain, or IgE having an ε heavy chain. In principle, the light chain includes either a κ chain or a λ chain.
[0028] [Multispecific antibodies] A multispecific antibody is an asymmetric antibody having two or more independent antigen recognition sites with two or more different antigen specificities, and examples thereof include a bispecific antibody having two antigen specificities, a trispecific antibody having three antigen specificities, etc. One or more antigens recognized by the multispecific antibody of the present invention are IL-33 molecules.
[0029] [Artificial antibody] An artificial antibody is, for example, a protein scaffold that does not have the structure of an antibody but has the same function as an antibody. Protein scaffolds include the Kunitz domain of human serine protease inhibitors, the extracellular domain of human fibronectin, ankyrin, lipocalin, etc., and by modifying the sequence of the target binding site on the scaffold, a protein scaffold that binds to the epitope of the present invention can be generated (Clifford Mintz et.al BioProcess International, 2013, Vol.11(2), pp40-48).
[0030] [Functionally modified antibodies] In the present application, a functionally modified antibody refers to an antibody whose cell-killing function, complement activation function, blood half-life, and the like other than the antigen-binding function of the antibody have been adjusted mainly by modifying the amino acids or glycans in the Fc region of the antibody.
[0031] [Conjugated antibodies] In the present application, a conjugated antibody refers to an antibody to which a functional molecule other than an antibody, such as a non-peptide polymer such as polyethylene glycol (PEG), a radioactive substance, a toxin, a low molecular weight compound, a cytokine, albumin, or an enzyme, is chemically or genetically bound.
[0032] [Fragment] In the present application, an antibody fragment refers to a protein containing a portion of an antibody and capable of binding to an antigen. Examples of antibody fragments include Fab fragments, Fv fragments, F(ab')2 fragments, Fab' fragments, and scFv. Furthermore, these antibody fragments may be chemically or genetically bound to functional molecules other than antibodies, such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, albumin, and enzymes.
[0033] [IL-33] IL-33 is a cytokine belonging to the IL-1 family, and human IL-33 consists of 270 amino acids as shown in SEQ ID NO: 226 in the sequence listing. IL-33 has a chromatin-binding domain on the N-terminus side, an IL-1-like cytokine domain with a molecular weight of 18 kDa and 12 β-strands on the C-terminus side, and further has cathepsin G cleavage sites at positions 95 and 109, an esterase cleavage site at position 99, and a caspase cleavage site at position 178 (Figure 1). During the process of cell necrosis, IL-33 is cleaved by enzymes such as esterase, cathepsin G, or proteinase 3 derived from lysosomes, and becomes various fragments including mature IL-33, for example, IL-33 (residues 95 to 270) (IL-33 represented by the amino acid sequence from the N-terminus of SEQ ID NO: 226 in the sequence listing is referred to as "IL-33 (residues 95 to 270)". The same notation will be used below), IL-33 (residues 99 to 270), IL-33 (residues 109 to 270), IL-33 (residues 112 to 270), etc., and is considered to function as a cytokine. On the other hand, when cell death is apoptosis, IL-33 is cleaved at position 178 by caspases activated during the apoptosis process, and becomes inactive IL-33, for example, IL-33 (residues 179 to 270).
[0034] When IL-33 is released extracellularly as a cytokine, it binds to the IL-33 receptor and initiates intracellular signal transduction in cells expressing the IL-33 receptor. Signal transduction induced by IL-33 includes, but is not limited to, the NF-κB pathway and the MAPKKs pathway, which ultimately induces the production of various cytokines, chemokines, and inflammatory mediators. Examples of cytokines induced by IL-33 include TNF-α, IL-1β, IFN-γ, IL-3, IL-4, IL-5, IL-6, IL-13, and the like, and in particular IFN-γ, IL-5, IL-6, and IL-13 are induced. Examples of chemokines induced by IL-33 include CXCL2, CCL2, CCL3, CCL6, CCL17, CCL24, and the like. Examples of inflammatory mediators induced by IL-33 include PGD2, LTB4, and the like. Cytokines, chemokines, and inflammatory mediators induced by IL-33 are involved in immune cell migration, cytokine production, and degranulation, causing inflammation. In the present invention, IL-33 may refer to either full-length IL-33 or an active fragment thereof, or a derivative or mutant thereof, so long as it acts by binding to the IL-33 receptor described below. In addition, IL-33 may be human IL-33 or IL-33 derived from other organisms. Among these, human IL-33 represented by the amino acid sequence of SEQ ID NO: 226 in the sequence listing is preferred.
[0035] The IL-33 receptor, to which IL-33 binds, is composed of a heterodimer of ST2 and IL-1RAcP (IL-1 receptor accessory protein). The site of the IL-33 receptor that specifically recognizes and binds to IL-33 is present in the extracellular domain of ST2. IL-33 receptors are expressed in various immune system cells (Th2 cells, mast cells, eosinophils, basophils, macrophages, dendritic cells, NK cells, NKT cells, group 2 innate lymphocytes (natural helper cells), nuocytes, Ih2 (innate helper type 2) cells, etc.) and epithelial cells, but are not limited to these cells.
[0036] [IL-33-related diseases] In the present application, IL-33-associated diseases refer to diseases caused by excessive extracellular release of IL-33, and IL-33-associated diseases can be prevented, treated, or alleviated by drugs capable of inhibiting the function of IL-33. Examples of IL-33-associated diseases include asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, hepatic fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[0037] [Framework area] The framework region refers to a portion of the variable region of an immunoglobulin molecule other than the complementarity determining region. There are four framework regions (framework region 1, framework region 2, framework region 3, and framework region 4) in each of the light chain and the heavy chain. In the present application, the framework regions of an immunoglobulin molecule are determined according to the Kabat numbering system (Kabat et al., 1987, Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA).
[0038] [Germline] A germline refers to a group of reproductive cells such as sperm and eggs, and unless otherwise specified, refers to the human germline. Unlike antibody-producing B lymphocytes, the immunoglobulin genes of germline cells do not undergo mutations. Therefore, when described as "amino acid sequence of germline framework regions," it means an amino acid sequence in which no mutations have occurred in the amino acid sequence of the immunoglobulin framework region, and when described as "amino acid sequence of a combination of amino acid sequences of germline framework regions," it means that one or more of the four framework regions have the amino acid sequence of a framework region of another germline. The genes of the light chain variable region of human immunoglobulin are divided into Vκ and Jκ segments in the κ chain and Vλ and Jλ segments in the λ chain, with framework region 1 to frame region 3 in the Vκ and Vλ segments, and framework region 4 in the Jκ and Jλ segments. The genes of the heavy chain variable region of human immunoglobulin are divided into VH, DH, and JH segments, with framework region 1 to frame region 3 in the VH segment, and framework region 4 in the JH segment. The germline amino acid sequences of the Vκ, Vλ, VH, Jκ, Jλ, and JH segments of human immunoglobulins are shown in Table 4.
[0039] [Table 4-1]
[0040] [Table 4-2]
[0041] [Table 4-3]
[0042] [Table 4-4]
[0043] [Human monoclonal antibody] A human monoclonal antibody refers to a monoclonal antibody having a variable region and a constant region derived from a human germline immunoglobulin sequence. In the present application, the variable region of a human monoclonal antibody may be a recombinant with a part or all of the variable region of another human monoclonal antibody, and in the recombinant, recombination may occur at the boundary between the framework region and the complementarity determining region from the viewpoint of not affecting the binding ability of the antibody, and each region of the framework region from framework region 1 to framework region 4 may be recombined with each region of the framework region from framework region 1 to framework region 4 of another human monoclonal antibody from the viewpoint of not increasing immunogenicity. Furthermore, in the present invention, the human monoclonal antibody may be a mutant of a human monoclonal antibody, and in order to reduce immunogenicity while maintaining or improving the binding ability to an antigen, a human monoclonal antibody containing an amino acid sequence of a complementarity determining region of a human monoclonal antibody having a mutation in the complementarity determining region and an amino acid sequence of a germline framework region having no mutation in the framework region is preferred.
[0044] [Isolated] The term "isolated" in the context of an isolated antibody means that it has been identified and separated and / or recovered from components in its natural state. Natural impurities are substances that may interfere with the diagnostic or therapeutic use of the antibody, including enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Generally, an antibody can be isolated by purification through at least one purification step, and an antibody purified through at least one purification step can be referred to as an "isolated antibody."
[0045] [Neutralization] In the present application, "neutralizing" refers to the ability to bind to a target of interest and inhibit any of the functions of that target. In other words, "anti-IL-33 neutralizing monoclonal antibody" refers to a monoclonal antibody whose binding to IL-33 results in inhibition of a biological activity induced by an IL-33 polypeptide. Inhibition of the biological activity of IL-33 includes, but is not limited to, inhibition of the production of IL-33-induced cytokines such as IL-6. Indicators of the biological activity of IL-33 can be assessed by one or more of several in vitro or in vivo assays known in the art. It should be noted that the term "human anti-IL-33 neutralizing monoclonal antibody" refers to a human monoclonal antibody that binds to IL-33 and inhibits any of the functions of IL-33.
[0046] [Antagonist] In the present application, the term "antagonist" refers collectively to a substance that has a neutralizing effect on a target of interest. That is, an "IL-33 antagonist" is a substance that can bind to IL-33 and inhibit any of the functions of IL-33, and includes, for example, an anti-IL-33 neutralizing monoclonal antibody.
[0047] [Complementarity determining region] A complementarity determining region refers to a region of an immunoglobulin molecule that forms an antigen-binding site, also called a hypervariable region, and refers to a portion in which the amino acid sequence varies significantly from one immunoglobulin molecule to another. There are three complementarity determining regions (complementarity determining region 1, complementarity determining region 2, and complementarity determining region 3) in each of the light chain and heavy chain. In this application, the complementarity determining regions of an immunoglobulin molecule are determined according to the Kabat numbering system (Kabat et al., 1987, Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA).
[0048] [Conflicting] In the present invention, "competing" with a monoclonal antibody means that the binding to IL-33 is significantly reduced in the presence of the monoclonal antibody when measured by the surface plasmon resonance (SPR) method described herein. In the present invention, the "competitive anti-IL-33 neutralizing monoclonal antibody" includes a chimeric antibody, a humanized antibody, a human antibody, a multispecific antibody, an artificial antibody, as well as functionally modified antibodies thereof, as well as conjugated antibodies thereof, and fragments thereof.
[0049] Hereinafter, embodiments of the present invention will be described. Note that the following embodiments are merely examples for explaining the present invention, and the present invention is not limited to these embodiments.
[0050] The present invention relates to a monoclonal antibody that binds to an epitope of IL-33. Since a monoclonal antibody that binds to this epitope can neutralize the activity of human IL-33, the epitope is preferably an amino acid sequence included in positions 101 to 154 or 199 to 270 of human IL-33 shown in SEQ ID NO: 226 of the Sequence Listing, and more preferably an amino acid sequence included in positions 111 to 130 (PEP12), 131 to 150 (PEP14), 231 to 250 (PEP24), or 251 to 270 (PEP26) of SEQ ID NO: 226 of the Sequence Listing. IL-33 is often cleaved when released outside the cells. When distant amino acid residues in the primary sequence of IL-33 form an epitope based on protein folding or the like, cleavage of IL-33 may disrupt folding or cause the distant amino acid residues constituting the epitope to disappear from the fragment, resulting in a significant decrease in affinity with the fragment. Therefore, the epitope to which an anti-IL-33 monoclonal antibody binds is preferably a continuous amino acid sequence.
[0051] For a monoclonal antibody that binds to an epitope to exert a neutralizing effect, it is necessary, for example, to prevent the binding of IL-33 to the IL-33 receptor. Therefore, in the present invention, a preferred epitope is not only located on the surface of the IL-33 protein, but is preferably located in close proximity to the IL-33 receptor. Thus, the present inventors performed three-dimensional structural modeling based on the crystal structure analysis data shown in Non-Patent Document 11 as described in the Examples below, and identified amino acids containing IL-33 atoms (interface atoms) that are within 5 Å of the nearest atom constituting the IL-33 receptor. Examples of amino acids containing interface atoms include P118 (the proline residue at position 118 of sequence number 226 in the sequence listing is represented as "P118"; hereinafter the same will be used), I119, T120, Y122, L123, R124, S125, L126, S127, Y129, and N130 of PEP12, D131, Q132, S133, T135, A137, L138, E139, S142, Y143, E144, I145, Y146, E148, D149, and L150 of PEP14, D244, N245, and H246 of PEP24, and K266, L267, S268, and E269 of PEP26. As a functional epitope to which a monoclonal antibody capable of neutralizing IL-33 specifically binds, an epitope having amino acids including interface atoms is preferred. The neutralizing effect of a monoclonal antibody that specifically binds to a functional epitope is thought to depend on the number of interface atoms present in the functional epitope, the position of the interface atoms in the three-dimensional structure, etc., but it is not intended to be bound by such theory.
[0052] A preferred embodiment of the present invention is a monoclonal antibody in which the epitope consisting of a continuous amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing is an epitope consisting of a continuous amino acid sequence of positions 111 to 130 (PEP12), 131 to 150 (PEP14), 231 to 250 (PEP24), or 251 to 270 (PEP26) of SEQ ID NO: 226 in the Sequence Listing. A more preferred embodiment of the present invention is a monoclonal antibody in which the epitope consisting of a continuous amino acid sequence of positions 138 to 147 or 139 to 147 of SEQ ID NO: 226 in the Sequence Listing.
[0053] The present inventors investigated the minimal amino acid sequence constituting the epitope using two types of monoclonal antibodies that bind to PEP14, and identified the consecutive amino acid sequences of positions 138 to 147 and 139 to 147 of SEQ ID NO: 226 in the Sequence Listing as the epitope of IL-33. Thus, the present invention relates to an epitope consisting of the consecutive amino acid sequences of positions 138 to 147 and 139 to 147 of SEQ ID NO: 226 in the Sequence Listing.
[0054] Whether a monoclonal antibody binds to the epitope of the present invention can be determined by methods commonly performed in the art, such as ELISA, immunoprecipitation, surface plasmon resonance (SPR), and KinExA. For example, in the peptide array scanning method described in the Examples of the present application using the SPR method, when tested using the epitope peptide of the present invention, the binding of the monoclonal antibody to the epitope can be measured as a significant increase in the RU value. In addition, the dissociation constant (Kd) can be measured by the method described in the Examples of the present application using the KinExA method, but the dissociation constant for the epitope peptide is preferably low, for example, 10 μM or less, 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, 100 pM or less, or 10 pM or less.
[0055] Another aspect of the present invention relates to a pharmaceutical composition comprising a monoclonal antibody of the present invention that binds to an epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the Sequence Listing. The present invention also relates to a method for diagnosing, treating, preventing or alleviating an IL-33-associated disease, which comprises administering the monoclonal antibody of the present invention, and use of the monoclonal antibody of the present invention for the manufacture of a medicament for diagnosing, treating, preventing or alleviating an IL-33-associated disease.
[0056] Examples of IL-33-associated diseases include, but are not limited to, asthma, atopic dermatitis, urticaria, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), allergic encephalomyelitis, hypereosinophilic syndrome, polymyalgia rheumatica, rheumatic heart disease, multiple sclerosis, arthritis (e.g., rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, osteoarthritis, Reiter's syndrome, etc.), systemic lupus erythematosus (including discoid lupus), pemphigus, pemphigoid, psoriasis, ankylosing spinal cord injury, and the like. Spondylitis, hepatitis (e.g., autoimmune hepatitis, chronic active hepatitis, etc.), inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, gluten-sensitive enteropathy, etc.), Sjogren's syndrome, autoimmune hemolytic anemia, autoimmune inflammatory eye disease, autoimmune neonatal thrombocytopenia, autoimmune neutropenia, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, autoimmune thyroiditis, polymyositis, dermatomyositis, myasthenia gravis, adrenergic agonist resistance, alopecia areata greata), antiphospholipid syndrome, autoimmune disorders of the adrenal gland (e.g., autoimmune Addison's disease), celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), cold agglutinin disease, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis (e.g., IgA nephrophathy), Graves' disease, hyperthyroidism (i.e., Hashimoto's thyroiditis), idiopathic thrombocytopenic purpura (ITP), mixed connective tissue disease, type 1 or immune-mediated diabetes mellitus, pernicious anemia, polychondritis (pol ychrondritis), polyglandular syndrome, stiff-man syndrome, vitiligo, sarcoidosis, polyendocrinopathy, other endocrine gland deficiencies, arteriosclerosis, liver fibrosis (e.g., primary biliary cirrhosis, etc.), pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis, etc.), chronic obstructive pulmonary disease (COPD), scleroderma (including CREST syndrome, Raynaud's phenomenon, etc.), tubulointerstitial nephritis, dense deposit disease, acute kidney injury, myocarditis, cardiomyopathy, neuritis (e.g., Guillain-Barré syndrome, etc.), polyarteritis nodosa, cardiotomy syndrome, chronic inflammatory demyelinating polyneuropathy, IgA neuropathy, lichen planus, Meniere's disease, post-myocardial infarction (post-MI), uveitis, uveitis ophthalmiaOpthalmia), vasculitis, primary agammaglobulinemia, cancer (e.g., brain tumor, laryngeal cancer, lip and oral cavity cancer, hypopharyngeal cancer, thyroid cancer, esophageal cancer, breast cancer, lung cancer, stomach cancer, adrenal cortical carcinoma, bile duct cancer, gallbladder cancer, liver cancer, pancreatic cancer, bladder cancer, colorectal cancer, uterine cancer, ovarian cancer, prostate cancer, testicular cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, Ewing's tumor, Hodgkin's disease, non-Hodgkin's lymphoma, melanoma, mesothelioma, multiple myeloma, etc.), infections that resist elimination by the immune system (e.g., severe acute respiratory syndrome). Examples of such diseases include acute respiratory syndrome (SARS), fatal cytokine storm associated with highly virulent influenza infection, and sepsis. Preferred examples of such diseases include asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, liver fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[0057] In yet another aspect, the present invention relates to an inhibitor of the expression of a cytokine, chemokine or inflammatory mediator, comprising a monoclonal antibody that binds to an epitope consisting of a consecutive amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO:226 in the sequence listing.
[0058] The cytokines suppressed by the cytokine, chemokine or inflammatory mediator expression inhibitor of the present invention are cytokines induced by IL-33, such as TNF-α, IFN-γ, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-13, etc. The chemokines suppressed by the inhibitor are induced by IL-33, such as CXCL2, CCL2, CCL3, CCL6, CCL17, CCL24, etc. The inflammatory mediators suppressed by the inhibitor are induced by IL-33, such as PGD2, LTB4, etc. A particularly preferred embodiment of the present invention is an expression inhibitor of IFN-γ, IL-5, IL-6 or IL-13, including an anti-IL-33 monoclonal antibody, and more preferably an IL-6 production inhibitor.
[0059] In yet another aspect of the present invention, the present invention relates to an epitope to which an anti-IL-33 monoclonal antibody binds. In the present invention, the epitope relates to a sequence consisting of 6 to 20 amino acids necessary for antibody recognition. In another aspect, an additional epitope may be formed by including amino acids surrounding the specified sequence or amino acids adjacent thereto in terms of three-dimensional structure, but it is preferable that the epitope is a continuous amino acid sequence that does not include discontinuous amino acid sequences.
[0060] Therefore, the number of amino acid residues in the consecutive amino acid sequence constituting the epitope of the present invention is at least 5, preferably at least 6, more preferably at least 7, even more preferably at least 8, and even more preferably at least 9. Furthermore, from the viewpoint of exerting more sufficient antigenicity, it is at least 10, more preferably 15, and even more preferably at least 20. On the other hand, if the sequence contained in the epitope is long, there is a possibility that it contains multiple parts recognized by the antibody, and in such a case, there is a possibility that it is not possible to generate or screen an antibody having the desired neutralizing effect. Therefore, from the viewpoint of ensuring that the antibody binding to the epitope of the present invention exerts the desired neutralizing effect, the length of the epitope sequence is preferably 30 or less, more preferably 20 or less, and even more preferably 15 or less. The number of residues in the consecutive amino acid sequence contained in the epitope is, for example, the number of residues selected from one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
[0061] The epitope may have one or several amino acid mutations, i.e., amino acid substitution, deletion, or insertion, introduced therein, so long as the antigenicity of the epitope is not changed. The number of mutations introduced is preferably 5 or less, more preferably 3 or less, and most preferably 1. Furthermore, the epitope may be modified, for example, modified with a sugar chain or terminal modification that the original protein had. In another embodiment, the epitope may have an amino acid sequence that has at least 90%, more preferably at least 95%, even more preferably at least 97%, even more preferably at least 98%, and most preferably 99% sequence identity with the sequence of consecutive amino acids of the epitope identified in the present invention, so long as the antigenicity of the epitope is not changed. For example, when the epitope peptide is used as a bait, a tag such as histidine or biotin may be added, and when used as a vaccine, it may be bound to a carrier protein such as KLH.
[0062] "Percent (%) sequence identity" with respect to a reference polypeptide sequence identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular reference polypeptide sequence after aligning the sequences, introducing gaps, if necessary, to obtain the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of measuring percent amino acid sequence identity can be achieved by a variety of methods within the skill of the art, such as using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the full length of the sequences being compared. However, for purposes herein, % amino acid sequence identity values are obtained by using the sequence comparison computer program BLAST in pairwise alignments. In situations where BLAST is used for amino acid sequence comparison, the percent amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B is calculated as follows: 100 times the fraction X / Y where X is the number of amino acid residues that score identical matches in a program alignment of A and B in the sequence alignment program BLAST, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is different from the length of amino acid sequence B, then the % amino acid sequence identity of A to B will differ from the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values herein are obtained using the BLAST computer program as set forth in the immediately preceding paragraph.
[0063] The epitopes found by the present invention are functional epitopes to which neutralizing antibodies of IL-33 specifically bind. Therefore, by utilizing the functional epitopes of the present invention, for example, novel antibodies having antagonistic activity against IL-33 can be efficiently obtained. That is, by screening a group of monoclonal antibodies against full-length IL-33 or mature IL-33 for antibodies that bind to the functional epitopes of the present invention, it becomes possible to obtain monoclonal antibodies having antagonistic activity. Therefore, in a further aspect of the present invention, the present invention also relates to a method for screening for antibodies having antagonistic activity using the functional epitopes of IL-33. More specifically, when enriching antibody clones having IL-33 antagonistic activity from a naive antibody library using phage display technology or the like, first, library selection is performed using full-length or mature IL-33 protein as bait to enrich antibody clones that bind to various epitopes on the surface of IL-33, and then library selection is performed using the functional epitope peptides discovered in the present invention as bait, making it possible to efficiently screen for antibodies having IL-33 antagonistic activity that specifically bind to functional epitopes.
[0064] In this example, the inventors investigated the IL-33 antagonistic activity of a group of monoclonal antibodies with specific binding to a 20-residue epitope by changing the antibody concentration. This allowed them to determine epitopes suitable for generating or screening antibodies with antagonistic activity. As a result, it was clearly observed that antibodies binding to epitopes selected from the group consisting of positions 111-130 (PEP12), 131-150 (PEP14), 231-250 (PEP24), and 251-271 (PEP26) of SEQ ID NO: 226 in the Sequence Listing showed an increase in antagonistic activity depending on the antibody concentration, and therefore these epitopes were found to be functional epitopes suitable for generating or screening antibodies with antagonistic activity. Thus, one aspect of the present invention relates to an epitope comprising a sequence consisting of at least 6, preferably at least 10, more preferably at least 15 consecutive amino acids in a region selected from the group consisting of positions 111 to 130, 131 to 150, 231 to 250, and 251 to 271 of SEQ ID NO: 226 in the Sequence Listing. In another aspect, the present invention relates to an epitope selected from the group consisting of positions 111 to 130, 131 to 150, 231 to 250, and 251 to 270 of SEQ ID NO: 226 in the Sequence Listing.
[0065] The epitope can be prepared by using conventional peptide synthesis techniques. The prepared and purified epitope can be used to immunize animals and generate antibodies against the epitope. Alternatively, the purified epitope can be used in a phage display method to generate or screen monoclonal antibodies that bind to the epitope. The epitope can also be used as a vaccine together with an adjuvant.
[0066] The present invention relates to a monoclonal antibody that binds to an epitope consisting of a continuous amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO: 226 in the sequence listing. The monoclonal antibody includes chimeric antibodies, humanized antibodies, human antibodies, multispecific antibodies, and artificial antibodies, as well as functionally modified antibodies thereof, conjugated antibodies thereof, and fragments thereof. The monoclonal antibody in the present invention may be an antibody derived from any animal, such as a mouse antibody, a human antibody, a rat antibody, a rabbit antibody, a goat antibody, or a camel antibody. The monoclonal antibody of the present invention can be produced using any known method, such as a hybridoma method, a phage display method, or a genetic engineering method.
[0067] In the hybridoma method, hybridomas are prepared by fusing B cells collected from the spleen or lymph nodes of an animal, particularly a rat or mouse, immunized with an immunogen with immortalized cells, such as myeloma cells, and the hybridomas that produce the desired binding properties are screened, and the antibody can be produced using the screened hybridomas. Also, human antibodies can be obtained by using mice introduced with human antibody genes. To obtain monoclonal antibodies from hybridomas, a method is adopted in which the hybridoma is cultured according to a conventional method and the culture supernatant is obtained, or a method is adopted in which the hybridoma is administered to a mammalian animal compatible with the hybridoma to grow the hybridoma and the ascites is obtained. The former method is suitable for obtaining high-purity antibodies, while the latter method is suitable for mass production of antibodies. A known technique may be used to prepare monoclonal antibodies, and the antibodies can be produced, for example, by following the description in Chapter 2 of Current Protocols in Immunology, Wiley and Sons Inc.
[0068] In the phage display method, phages selected from an arbitrary phage antibody library are screened using a target immunogen to select a phage having a desired binding property to the immunogen. Next, the antibody-corresponding sequence contained in the phage is isolated or sequenced, and an expression vector containing a nucleic acid molecule encoding a monoclonal antibody is constructed based on the isolated sequence or the sequence information determined. Then, a cell line transfected with such an expression vector is cultured to produce a monoclonal antibody. By using a human antibody library as the phage antibody library, a human antibody having a desired binding property can be generated.
[0069] In genetic engineering techniques, a mutation can be introduced into a sequence corresponding to a complementarity determining region (CDR) or other sequence in a gene sequence encoding an antibody, and the sequence can be incorporated into an expression vector, which can then be transformed into a host cell to produce a recombinant antibody (see, for example, Borrebaeck CAK and Larrick JW THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990).
[0070] In the present invention, for example, chimeric antibodies, humanized antibodies, multispecific antibodies, and artificial antibodies can also be used for the purpose of reducing heterologous antigenicity against humans or adding other functions, and these antibodies can be produced using known methods.
[0071] A chimeric antibody can be obtained by linking DNA encoding a non-human antibody variable region to DNA encoding a human antibody constant region, incorporating the resultant into an expression vector, and introducing the vector into a host for production (see EP 125023, WO 92 / 19759). Using this known method, a chimeric antibody useful in the present invention can be obtained.
[0072] Humanized antibodies can be obtained by linking the complementarity determining regions (CDRs) of a non-human antibody to DNA encoding the remaining human antibody regions, incorporating this into an expression vector, and introducing it into a host for production.
[0073] A multispecific antibody is an asymmetric antibody that has two or more independent antigen recognition sites with two or more different antigen specificities. Multispecific antibodies such as bispecific antibodies can be produced by genetic engineering techniques using the antigen-binding regions of two or more monoclonal antibodies. Such genetic engineering techniques have already been established in this field. For example, the desired bispecific antibody can be obtained by using the DVD-Ig technology (Wu et al., Nature Biotechnology 25(11), 1290(2007)) in which the antigen-binding regions of two types of monoclonal antibodies are linked in series, or the ART-Ig technology (Kitazawa et al., Nature Medicine 18(10), 1570(2012)) in which the heavy chains of two types of antibodies that bind to different antigens are combined by modifying the Fc region of the antibody.
[0074] An artificial antibody is, for example, a protein scaffold that does not have the structure of an antibody but has the same function as an antibody. Protein scaffolds include the Kunitz domain of human serine protease inhibitors, the extracellular domain of human fibronectin, ankyrin, lipocalin, etc., and by modifying the sequence of the target binding site on the scaffold, a protein scaffold that binds to the epitope of the present invention can be generated (Patent Document 4, Clifford Mintz et.al BioProcess International, 2013, Vol.11(2), pp40-48).
[0075] By modifying the amino acid sequence or sugar chain of the Fc region of the monoclonal antibody of the present invention, the cell killing function, complement activation function, blood half-life, and the like, other than the antigen binding function of the antibody, can be adjusted (Strohl, Current Opinion in Biotechnology, 2009, vol.20, p685). Such functionally modified antibodies are prepared, for example, by the following method. When a monoclonal antibody is produced using CHO cells in which the α1,6-fucosyltransferase (FUT8) gene has been disrupted as host cells, an antibody with a reduced fucose content in the sugar chain and enhanced cell killing function can be obtained, and when a CHO cell into which the FUT8 gene has been introduced is used as a host cell, an antibody with a reduced cell killing function can be obtained (WO 2005 / 035586, WO 2002 / 31140, WO 00 / 61739). In addition, complement activation function can be regulated by modifying amino acid residues in the Fc region (U.S. Patent No. 6,737,056, U.S. Patent No. 7,297,775, U.S. Patent No. 7,317,091). Furthermore, the half-life in blood can be extended by using a mutant Fc region that enhances binding to FcRn, one of the Fc receptors (Hashiguchi Shuhei et al., Seikagaku, 2010, Vol. 82(8), p. 710). These functionally modified antibodies can be produced by genetic engineering.
[0076] The monoclonal antibody used in the present invention may be a conjugated antibody bound to various molecules such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, and toxins. Such conjugated antibodies can be obtained by chemically modifying the obtained antibody. Chemical modification methods have already been established in this field. The monoclonal antibody in the present invention also includes these conjugated antibodies (DJ King., Applications and Engineering of Monoclonal antibodies., 1998 TJ International Ltd, Monoclonal Antibody-Based Therapy of Cancer., 1998 Marcel Dekker Inc; Chari et al., Cancer Res., 1992 Vol152:127; Liu et al., Proc Natl Acad Sci USA., 1996 Vol 93:8681, ).
[0077] In the present invention, apart from the whole antibodies as described above, monoclonal antibody fragments or modified products thereof may be used as long as they have epitope binding ability and exhibit antagonist activity. Examples of antibody fragments include Fab fragments, Fv fragments, F(ab')2 fragments, Fab' fragments, and single chain Fvs (scFvs) in which the H and L chains of Fv are linked via an appropriate linker. Furthermore, these antibody fragments may be chemically or genetically bound to functional molecules other than antibodies, such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, albumin, and enzymes.
[0078] The production system for producing monoclonal antibodies can be either an in vitro or in vivo production system. In vitro production systems include production systems using eukaryotic cells, such as animal cells, plant cells, or fungal cells, and prokaryotic cells, such as bacterial cells, such as E. coli and Bacillus subtilis. The animal cells used may be mammalian cells, such as commonly used cells, such as CHO, COS, myeloma, BHK, HeLa, and Vero, insect cells, and plant cells. In vivo production systems include production systems using animals and production systems using plants. When animals are used, there are, for example, production systems using mammals and insects. As mammals, for example, goats, pigs, sheep, mice, and cows can be used (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). As insects, for example, silkworms can be used. When plants are used, for example, tobacco can be used.
[0079] When producing monoclonal antibodies in an in vitro or in vivo production system as described above, DNA encoding the monoclonal antibody heavy chain (H chain) and light chain (L chain) may be separately incorporated into expression vectors and co-transformed into the host, or DNA encoding the H chain and L chain may be incorporated into a single expression vector and used to transform the host (see International Publication No. WO94 / 11523).
[0080] The obtained monoclonal antibody can be purified to homogeneity. Separation and purification of monoclonal antibodies can be performed using methods used for separating and purifying proteins. For example, the monoclonal antibody can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, etc. (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988), but is not limited thereto. Examples of columns used for affinity chromatography include protein A columns and protein G columns. For example, examples of columns using protein A columns include Hyper D, POROS, Sepharose FF (Amersham Biosciences), etc.
[0081] The monoclonal antibody of the present invention that binds to an epitope consisting of a continuous amino acid sequence included in positions 101 to 154 or 199 to 270 of SEQ ID NO:226 in the Sequence Listing has low antigenicity when administered to humans, and is therefore preferably a chimeric antibody, a humanized antibody, or a human antibody, and most preferably a human antibody. Furthermore, among human antibodies, it is preferable that the amino acid sequence of the framework region is the amino acid sequence of a human germline framework region or a combination thereof. Thus, the present invention relates to a human anti-IL-33 neutralizing monoclonal antibody, in which the amino acid sequence of the framework region of the antibody is the amino acid sequence of a germline framework region or a combination thereof. This human anti-IL-33 neutralizing monoclonal antibody has the characteristic that the framework regions of the variable regions contain the amino acid sequences of human germline framework regions or a combination thereof, and thus has no or significantly less immunogenicity due to these regions, while being able to bind to IL-33 and interfere with its function. Therefore, when used as a medicine, the antibody is unlikely to induce human anti-human immunoglobulin antibodies (HAHA) and is therefore not eliminated in the body, and as a result, it has a long-lasting effect of neutralizing IL-33 and is a safe antibody as long as it does not cause inflammation due to binding to HAHA.
[0082] Any amino acid sequence of the framework region of the light chain and the heavy chain in the human germline can be used as long as it is an amino acid sequence of the framework region of the human germline. For example, an amino acid sequence encoded by the DNA sequence of the framework region of the heavy chain variable region and the light chain variable region of a human antibody registered in a database such as NCBI (http: / / www.ncbi.nlm.nih.gov / igblast / showGermline.cgi) or an amino acid sequence of the framework region of the germline described in Table 4 can be used. The light chain variable region may be a variable region of a λ chain or a variable region of a κ chain. As the framework region of the light chain and the heavy chain in the human germline, a framework region that is frequently used in vivo and has a high frequency of occurrence is preferable. Examples of such a human heavy chain framework region include framework region 1, framework region 2, and framework region 3 such as VH3-23, VH3-30, VH4-39, and VH4-34, and framework region 4 such as JH4. Examples of human light chain framework regions that frequently appear in vivo include framework region 1, framework region 2, and framework region 3 of Vλ1-47, Vλ2-14, Vκ3-20, Vκ1-39, etc., and framework region 4 of Jλ2, etc. Heavy chain framework regions can be used in any combination so long as they are human heavy chain framework regions, for example, framework region 1 and framework region 2 of VH3-23 and framework region 3 of VH3-30 can be selected and used as the heavy chain framework region. Similarly, light chain framework regions can be used in any combination so long as they are human light chain framework regions.
[0083] In the present application, preferred amino acid sequences of the germline framework regions are the amino acid sequences of the framework regions of VH3-23, VH3-30, JH4, Vλ1-47, and Jλ2. Specifically, the amino acid sequence of the light chain framework region 1 is residues 1 to 22 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 2 is residues 36 to 50 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 3 is residues 58 to 89 of SEQ ID NO: 317 in the Sequence Listing, and the amino acid sequence of the light chain framework region 4 is residues 3 to 12 of SEQ ID NO: 401 in the Sequence Listing, and the amino acid sequence of the heavy chain framework region 1 is residues 1 to 30 of SEQ ID NO: 367 in the Sequence Listing or residues 1 to 30 of SEQ ID NO: 368 in the Sequence Listing, the amino acid sequence of the heavy chain framework region 2 is residues 36 to 49 of SEQ ID NO: 367 in the Sequence Listing or residues 36 to 49 of SEQ ID NO: 368 in the Sequence Listing, the amino acid sequence of the heavy chain framework region 3 is residues 67 to 98 of SEQ ID NO: 367 in the Sequence Listing or residues 67 to 98 of SEQ ID NO: 368 in the Sequence Listing, and the amino acid sequence of the heavy chain framework region 4 is A framework region having a sequence of residues 5 to 15 of SEQ ID NO: 407 in the Sequence Listing is preferred, and a framework region having an amino acid sequence of the light chain framework region 1 having a sequence of residues 1 to 22 of SEQ ID NO: 317 in the Sequence Listing, an amino acid sequence of the light chain framework region 2 having a sequence of residues 36 to 50 of SEQ ID NO: 317 in the Sequence Listing, an amino acid sequence of the light chain framework region 3 having a sequence of residues 58 to 89 of SEQ ID NO: 317 in the Sequence Listing, and an amino acid sequence of the light chain framework region 4 having a sequence of residues 3 to 12 of SEQ ID NO: 401 in the Sequence Listing, and a framework region having an amino acid sequence of the heavy chain framework region 1 having a sequence of residues 1 to 30 of SEQ ID NO: 367 in the Sequence Listing, an amino acid sequence of the heavy chain framework region 2 having a sequence of residues 36 to 49 of SEQ ID NO: 367 in the Sequence Listing, an amino acid sequence of the heavy chain framework region 3 having a sequence of residues 67 to 98 of SEQ ID NO: 368 in the Sequence Listing, and an amino acid sequence of the heavy chain framework region 4 having a sequence of residues 5 to 15 of SEQ ID NO: 407 in the Sequence Listing is most preferred.
[0084] Another aspect of the present invention relates to an isolated human anti-IL-33 neutralizing monoclonal antibody, in which the amino acid sequences of light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2) and heavy chain complementarity determining region 3 (HCDR3) are the amino acid sequences of a combination of complementarity determining regions shown in Table 1.
[0085] In a more preferred embodiment, a human anti-IL-33 neutralizing monoclonal antibody having a combination of the complementarity determining regions C1 to C30 shown in Table 1 has binding activity and neutralizing activity against IL-33, particularly against mature IL-33 that binds to the IL-33 receptor and exerts activity, such as IL-33 (residues 95 to 270), IL-33 (residues 99 to 270), IL-33 (residues 109 to 270), IL-33 (residues 112 to 270), etc. More preferably, a human anti-IL-33 neutralizing monoclonal antibody having a combination of the complementarity determining regions C1 to C30 shown in Table 1 has binding activity against IL-33 (residues 131 to 150).
[0086] In the present invention, a preferred embodiment is a combination of complementarity determining regions that are improved in terms of binding affinity and / or physical properties. Particularly preferred is a combination of complementarity determining regions that has an upper limit of the dissociation rate constant (koff) for human IL-33 of about 3.5×10 -5 / sec or less, and more preferably about 2.0×10 -5 / sec or less, more preferably about 1.5×10 -5 / sec or less, and even more preferably about 1.0×10 -5 / sec or less, and the lower limit is not particularly limited, but may be, for example, 10 -7 / sec or more, preferably 10 -6 / sec or more, and more preferably about 5×10 -6 / sec or more.
[0087] Among human anti-IL-33 neutralizing monoclonal antibodies, those with a low dissociation constant (Kd) for human IL-33 are more preferred, with the upper limit being, for example, 10 -9 M or less, more preferably 10 -10 M or less, and even more preferably 10 -12 M or less, and the lower limit is not particularly limited, but for example, 10 -14 M or more, more preferably 10 -13 The above-mentioned human anti-IL-33 neutralizing monoclonal antibodies are examples of such human anti-IL-33 neutralizing monoclonal antibodies.
[0088] The human anti-IL-33 neutralizing monoclonal antibody of the present invention inhibits IL-6 production from HUVECs stimulated with IL-33, and among these, those with a strong inhibitory effect are preferred. Specifically, as described in Example 10 below, preferred embodiments of the present invention include a human anti-IL-33 neutralizing monoclonal antibody that inhibits IL-6 production from HUVECs stimulated with 100 ng / mL of IL-33 by the addition of 1 μg / mL of the human anti-IL-33 neutralizing monoclonal antibody by about 50% or more (inhibition rate), more preferably about 70% or more, and even more preferably about 90% or more.
[0089] The human anti-IL-33 neutralizing monoclonal antibody of the present invention inhibits the production of IL-5, IL-6 and / or IL-13 from KU-812 cells upon stimulation with IL-33. Among them, those with a strong inhibitory effect are preferred. Specifically, as described in Example 11 below, a preferred embodiment of the present invention is a human anti-IL-33 neutralizing monoclonal antibody that inhibits the production of IL-5, IL-6 and / or IL-13 from KU-812 cells upon stimulation with 100 ng / mL of IL-33 by the addition of 3 μg / mL of the human anti-IL-33 neutralizing monoclonal antibody by about 30% or more (inhibition rate), more preferably about 50% or more, and even more preferably about 70% or more.
[0090] The human anti-IL-33 neutralizing monoclonal antibody of the present invention inhibits the production of IFN-γ from human peripheral blood mononuclear cells when stimulated with IL-33. Among them, those with a strong inhibitory effect are preferred. Specifically, as described in Example 12 below, a preferred embodiment of the present invention is a human anti-IL-33 neutralizing monoclonal antibody that inhibits the production of IFN-γ from human peripheral blood mononuclear cells stimulated with 10 ng / mL of IL-33 by about 80% or more (inhibition rate) when added with 10 μg / mL of the human anti-IL-33 neutralizing monoclonal antibody, more preferably about 90% or more, and even more preferably about 95% or more.
[0091] The human anti-IL-33 neutralizing monoclonal antibody of the present invention suppresses inflammation when human IL-33 is administered to mice. Among them, those with a strong anti-inflammatory effect are preferred. Specifically, as described in Example 13 below, a preferred embodiment of the present invention is a human anti-IL-33 neutralizing monoclonal antibody that, when intraperitoneally administered at 10 mg / kg for 7 consecutive days, suppresses increases in spleen weight, serum IgA concentration, serum IgE concentration, neutrophil count, basophil count, eosinophil count, and / or serum IL-5 concentration caused by continuous administration of 0.4 μg / individual of human IL-33 for 7 consecutive days by about 30% or more, more preferably about 50% or more, and even more preferably about 80% or more.
[0092] Furthermore, the human anti-IL-33 neutralizing monoclonal antibody of the present invention preferably has excellent physical properties, and is particularly preferably a human anti-IL-33 neutralizing monoclonal antibody that does not show a bimodal particle size distribution shape as evaluated by dynamic light scattering and has extremely low aggregation properties, and is preferably one that has a high interaction parameter (kD), which is an index of colloidal stability, for example, preferably -12.4 mL / g or more, more preferably -10 mL / g or more, and even more preferably -8.5 mL / g or more. The human anti-IL-33 neutralizing monoclonal antibody of the present invention is preferably an antibody with excellent thermodynamic stability, for example, an antibody exhibiting thermodynamic stability such that the temperature (Tm) at which the folding of the immunoglobulin domain collapses is 65°C or higher, preferably 68°C or higher, more preferably 70°C or higher, and even more preferably 73°C or higher.
[0093] Furthermore, the human anti-IL-33 neutralizing monoclonal antibody of the present invention preferably has excellent antibody stability. Antibody stability can be measured by common techniques such as storage stability tests and forced oxidation tests. In a preferred embodiment of the present invention, for example, a storage stability test is one in which the monomer ratio of the antibody molecule is preferably 90% or more, more preferably 95% or more, and the binding activity to human IL-33 protein is preferably 95% or more, more preferably 99% or more, after storage at 40°C for 4 weeks, as described in Example 21 below. Furthermore, as described in Example 22 of the present application, when forcibly oxidized with 1% hydrogen peroxide at 37°C for 24 hours, it is preferable that the binding activity to human IL-33 protein is maintained at 80% or more, more preferably at least 85%, and even more preferably at least 90%.
[0094] Considering the above, in the present invention, a human anti-IL-33 neutralizing monoclonal antibody selected from the combination of complementarity determining regions C1 to C28 in Table 1 is more preferred. Further preferred embodiments of the present invention include human anti-IL-33 neutralizing monoclonal antibodies having a specific combination of amino acid sequences of complementarity determining regions (C1, C8, C15, C17, or C18 in Table 1).
[0095] The amino acid sequence of the framework region in the variable region of the human anti-IL-33 neutralizing monoclonal antibody specified by the above combination of amino acid sequences of the complementarity determining regions may be any framework region as long as antigen-binding ability is ensured. From the viewpoint of reducing immunogenicity in humans, the amino acid sequence of the framework region is preferably each amino acid sequence of a human germline framework region or a combination thereof, and more preferably is an amino acid sequence of a germline framework region that is frequently used in the human body.
[0096] In the present invention, the amino acid sequence of the framework region is preferably such that the amino acid sequence of the light chain framework region 1 is from residue 1 to residue 22 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 2 is from residue 36 to residue 50 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of the light chain framework region 3 is from residue 58 to residue 89 of SEQ ID NO: 317 in the Sequence Listing, and the amino acid sequence of the light chain framework region 4 is from residue 3 to residue 12 of SEQ ID NO: 401 in the Sequence Listing, and the amino acid sequence of the heavy chain framework region 2 is residues 36 to 49 of SEQ ID NO: 367 in the Sequence Listing or residues 1 to 30 of SEQ ID NO: 368 in the Sequence Listing; the amino acid sequence of the heavy chain framework region 3 is residues 67 to 98 of SEQ ID NO: 367 in the Sequence Listing or residues 67 to 98 of SEQ ID NO: 368 in the Sequence Listing; and the amino acid sequence of the heavy chain framework region 4 is residues 5 to 15 of SEQ ID NO: 407 in the Sequence Listing. More preferred amino acid sequences of the framework regions in the present invention are as follows: the amino acid sequence of light chain framework region 1 is residues 1 to 22 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of light chain framework region 2 is residues 36 to 50 of SEQ ID NO: 317 in the Sequence Listing, the amino acid sequence of light chain framework region 3 is residues 58 to 89 of SEQ ID NO: 317 in the Sequence Listing, and the amino acid sequence of light chain framework region 4 is residues 3 to 12 of SEQ ID NO: 401 in the Sequence Listing; and the amino acid sequence of heavy chain framework region 1 is residues 1 to 30 of SEQ ID NO: 367 in the Sequence Listing, the amino acid sequence of heavy chain framework region 2 is residues 36 to 49 of SEQ ID NO: 367 in the Sequence Listing, the amino acid sequence of heavy chain framework region 3 is residues 67 to 98 of SEQ ID NO: 368 in the Sequence Listing, and the amino acid sequence of heavy chain framework region 4 is residues 5 to 15 of SEQ ID NO: 407 in the Sequence Listing.
[0097] Therefore, preferred combinations of amino acid sequences of heavy chain variable regions and light chain variable regions in the present invention are shown in Table 2, for example.
[0098] A preferred embodiment of the present invention is a human anti-IL-33 neutralizing monoclonal antibody having a combination of variable regions V1 to V28 in Table 2.
[0099] A more preferred embodiment of the present invention is a human anti-IL-33 neutralizing monoclonal antibody having a specific combination of amino acid sequences in the complementarity determining regions (V1, V8, V15, V17 or V18 in Table 2).
[0100] Human immunoglobulin molecules include IgG (including IgG1, IgG2, IgG3, and IgG4), IgM, IgA (including IgA1 and IgA2), IgD, and IgE, which have heavy chains of γ, μ, α, δ, or ε, respectively, depending on the constant region of the heavy chain, and the constant region of the human anti-IL-33 neutralizing monoclonal antibody of the present invention includes all of them. In addition, light chains include κ and λ chains depending on their location on the chromosome, and both are included. When producing antibody pharmaceuticals, κ chains are preferred from the viewpoint of aggregation, but antibodies having a λ light chain are also useful in that the λ chain has an amino acid sequence different from that of the κ chain and is as diverse as the κ chain. From the viewpoint of blood stability, the human anti-IL-33 neutralizing monoclonal antibody of the present invention is preferably an IgG with a λ light chain and a γ heavy chain, and more preferably an IgG1 with a λ light chain and a γ1 heavy chain.
[0101] Since the amino acid sequence of IL-33 varies depending on the animal species, there is also a difference in the amino acid sequence between human IL-33 shown in SEQ ID NO: 226 in the Sequence Listing and monkey IL-33 shown in SEQ ID NO: 227 in the Sequence Listing. Generally, monkeys are used as experimental materials in pharmacological tests and safety tests of antibody drugs, so the human anti-IL-33 neutralizing monoclonal antibody of the present invention preferably binds to monkey IL-33 as well, and more preferably binds to monkey IL-33 with the same affinity as human IL-33. Particularly preferred is a human anti-IL-33 neutralizing monoclonal antibody in which the ratio of koff for monkey IL-33 to human IL-33 is within about 20 times, more preferably within about 10 times, and even more preferably within about 5 times.
[0102] Examples of antibody fragments of the present invention include Fab fragments, Fv fragments, F(ab')2 fragments, Fab' fragments, and scFv. Furthermore, these antibody fragments may be bound to functional molecules other than antibodies, such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, albumin, and enzymes.
[0103] The human anti-IL-33 neutralizing monoclonal antibody of the present invention can be bound to an antibody having an antigen-binding specificity other than IL-33 to prepare a multispecific antibody such as a bispecific antibody. Examples of antigens other than IL-33 include, but are not limited to, TNF-α, IL-6 receptor, CD3, CD20, α4 integrin, BLys, thymic stromal lymphopoietin, IgE, IL-1, IL-2, IL-4, IL-5, IL-6, IL-13, IL-17, IL-23, and IL-25.
[0104] In the human anti-IL-33 neutralizing monoclonal antibody of the present invention and a fragment of the antibody, functionally modified antibodies having adjusted functions such as cell killing function, complement activation function, and blood half-life can be obtained by modifying the Fc region, etc. (Shitara Kenya, Yakugaku Zasshi, 2009, Vol. 129(1), p. 3; Ishii Akiko et al., Pharmacology Japan Journal, 2010, Vol. 136(5), p. 280; Hashiguchi Shuhei et al., Seikagaku, 2010, Vol. 82(8), p. 710, Strohl, Current Opinion in Biotechnology, 2009, Vol. 20, p. 685).
[0105] The human anti-IL-33 neutralizing monoclonal antibody of the present invention and a fragment of the antibody can be bound to other functional molecules to form a conjugate antibody, and new functions can be added by binding functional molecules such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, albumin, cytokines, and enzymes.
[0106] Other aspects of the present invention include a nucleic acid molecule encoding a protein portion of a human anti-IL-33 neutralizing monoclonal antibody whose framework region is a germline amino acid sequence, a vector comprising the nucleic acid molecule, a host cell comprising the vector, and a method for producing a human anti-IL-33 neutralizing monoclonal antibody by culturing the host cell.
[0107] In yet another aspect, the present invention also relates to a composition comprising the above-mentioned human anti-IL-33 neutralizing monoclonal antibody. Since IL-33 induces inflammation, etc., the human anti-IL-33 neutralizing monoclonal antibody is expected to be used for the diagnosis, treatment, prevention, or alleviation of IL-33-related diseases. Thus, in one aspect, the present invention also relates to a pharmaceutical composition for the diagnosis, treatment, prevention, or alleviation of IL-33-related diseases, comprising a human anti-IL-33 neutralizing monoclonal antibody. In yet another aspect, since IL-33 induces cytokines, chemokines, inflammatory mediators, etc., the present invention also relates to an inhibitor of cytokine, chemokine, or inflammatory mediator expression, comprising a human anti-IL-33 neutralizing monoclonal antibody.
[0108] The cytokines suppressed by the cytokine, chemokine or inflammatory mediator expression inhibitor of the present invention are cytokines induced by IL-33, such as TNF-α, IFN-γ, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-13, etc. The chemokines suppressed by the inhibitor are induced by IL-33, such as CXCL2, CCL2, CCL3, CCL6, CCL17, CCL24, etc. The inflammatory mediators suppressed by the inhibitor are induced by IL-33, such as PGD2, LTB4, etc. A particularly preferred embodiment of the present invention is an expression inhibitor of IFN-γ, IL-5, IL-6 or IL-13, including a human anti-IL-33 neutralizing monoclonal antibody, and more preferably an IL-6 production inhibitor.
[0109] Further aspects of the invention relate to pharmaceutical compositions comprising the monoclonal antibodies of the invention, as well as to methods for the diagnosis, treatment, prevention or amelioration of IL-33-related diseases comprising administering the monoclonal antibodies of the invention, and to the use of the monoclonal antibodies of the invention for the manufacture of a medicament for the diagnosis, treatment, prevention or amelioration of IL-33-related diseases.
[0110] Examples of IL-33-associated diseases include, but are not limited to, asthma, atopic dermatitis, urticaria, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), allergic encephalomyelitis, hypereosinophilic syndrome, polymyalgia rheumatica, rheumatic heart disease, multiple sclerosis, arthritis (e.g., rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, osteoarthritis, Reiter's syndrome, etc.), systemic lupus erythematosus (including discoid lupus), pemphigus, pemphigoid, psoriasis, ankylosing spinal cord injury, and the like. Spondylitis, hepatitis (e.g., autoimmune hepatitis, chronic active hepatitis, etc.), inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, gluten-sensitive enteropathy, etc.), Sjogren's syndrome, autoimmune hemolytic anemia, autoimmune inflammatory eye disease, autoimmune neonatal thrombocytopenia, autoimmune neutropenia, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, autoimmune thyroiditis, polymyositis, dermatomyositis, myasthenia gravis, adrenergic agonist resistance, alopecia areata greata), antiphospholipid syndrome, autoimmune disorders of the adrenal gland (e.g., autoimmune Addison's disease), celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), cold agglutinin disease, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis (e.g., IgA nephrophathy), Graves' disease, hyperthyroidism (i.e., Hashimoto's thyroiditis), idiopathic thrombocytopenic purpura (ITP), mixed connective tissue disease, type 1 or immune-mediated diabetes mellitus, pernicious anemia, polychondritis (pol ychrondritis), polyglandular syndrome, stiff-man syndrome, vitiligo, sarcoidosis, polyendocrinopathy, other endocrine gland deficiencies, arteriosclerosis, liver fibrosis (e.g., primary biliary cirrhosis, etc.), pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis, etc.), chronic obstructive pulmonary disease (COPD), scleroderma (including CREST syndrome, Raynaud's phenomenon, etc.), tubulointerstitial nephritis, dense deposit disease, acute kidney injury, myocarditis, cardiomyopathy, neuritis (e.g., Guillain-Barré syndrome, etc.), polyarteritis nodosa, cardiotomy syndrome, chronic inflammatory demyelinating polyneuropathy, IgA neuropathy, lichen planus, Meniere's disease, post-myocardial infarction (post-MI), uveitis, uveitis ophthalmiaOpthalmia), vasculitis, primary agammaglobulinemia, cancer (e.g., brain tumor, laryngeal cancer, lip and oral cavity cancer, hypopharyngeal cancer, thyroid cancer, esophageal cancer, breast cancer, lung cancer, stomach cancer, adrenal cortical carcinoma, bile duct cancer, gallbladder cancer, liver cancer, pancreatic cancer, bladder cancer, colorectal cancer, uterine cancer, ovarian cancer, prostate cancer, testicular cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, Ewing's tumor, Hodgkin's disease, non-Hodgkin's lymphoma, melanoma, mesothelioma, multiple myeloma, etc.), infections that resist elimination by the immune system (e.g., severe acute respiratory syndrome). Examples of such diseases include acute respiratory syndrome (SARS), fatal cytokine storm associated with highly virulent influenza infection, and sepsis. Preferred examples of such diseases include asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, liver fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
[0111] The pharmaceutical composition containing the human anti-IL-33 neutralizing monoclonal antibody of the present invention may contain a pharmacologically acceptable carrier, diluent or excipient in addition to the human anti-IL-33 neutralizing monoclonal antibody and a salt thereof as an active ingredient. It may further contain other active ingredients other than the human anti-IL-33 neutralizing monoclonal antibody of the present invention, such as anti-inflammatory drugs and immunosuppressants. Such a composition is provided in a dosage form suitable for parenteral or oral administration, but parenteral administration is preferred from the viewpoint of use as an antibody pharmaceutical. Examples of parenteral administration include, but are not limited to, intravenous, intraarterial, subcutaneous, topical, intraperitoneal, intramuscular, nasal, ophthalmic, transdermal, transmucosal, intrameningeal, rectal, intramuscular, and intracerebral administration.
[0112] The pharmaceutical composition may be appropriately formulated according to the route of administration, and may be, for example, an injection, a powder, an infusion preparation, granules, tablets, suppositories, etc. From the viewpoint of parenteral administration, preferred are an injection, an infusion preparation, a powder that dissolves when used, etc. Furthermore, these preparations may contain various adjuvants used in medicine, that is, carriers and other auxiliary agents, such as additives such as stabilizers, preservatives, soothing agents, emulsifiers, etc.
[0113] The human anti-IL-33 neutralizing monoclonal antibodies of the present invention can be provided by continuous infusion or by dosing, for example, at intervals of once a day, once a week, once a month, or once to seven times a year. Dosing can be provided intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscularly, intracerebroventricularly, or by inhalation. A preferred dosing protocol is one that includes the maximum dose or dosing frequency that avoids significant undesirable side effects. The total weekly dose will generally be at least about 0.05 μg / kg body weight, more generally at least about 0.2 μg / kg, most generally at least about 0.5 μg / kg, typically at least about 1 μg / kg, more typically at least about 10 μg / kg, and most typically at least about 100 μg / kg, preferably at least about 0.2 mg / kg, more preferably at least about 1.0 mg / kg, most preferably at least about 2.0 mg / kg, optimally at least about 10 mg / kg, more optimally at least about 25 mg / kg, and most optimally at least about 50 mg / kg.
[0114] The human anti-IL-33 neutralizing monoclonal antibodies of the present invention are useful in diagnostic assays, for example, for detecting the expression of IL-33 in specific cells, tissues, or serum of patients with IL-33-related diseases. Typically, for diagnostic applications, it is preferred that the human anti-IL-33 neutralizing monoclonal antibodies are conjugated antibodies labeled with a detectable moiety.
[0115] Another aspect of the present invention relates to an anti-IL-33 neutralizing monoclonal antibody that competes for binding to IL-33 with an anti-IL-33 neutralizing monoclonal antibody comprising a specific combination of amino acid sequences in complementarity determining regions (C1, C8, C15, C17 or C18 in Table 1) or a specific combination of amino acid sequences in variable regions (V1, V8, V15, V17 or V18 in Table 2).
[0116] An anti-IL-33 neutralizing monoclonal antibody that competes with a human anti-IL-33 neutralizing monoclonal antibody comprising a specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions as described above for binding to IL-33 can be obtained by screening anti-IL-33 antibodies obtained by genetic engineering techniques such as phage display or the hybridoma method, for example, by the following surface plasmon resonance (SPR) method.
[0117] Biotinylated human IL-33 protein (4 μg / mL) is loaded as a ligand onto the avidin-immobilized sensor chip, immobilizing 1300 to 1600 RU of human IL-33 protein. Next, any anti-IL-33 antibody (15 μg / mL) is loaded as an analyte and allowed to bind to the human IL-33 protein immobilized on the sensor chip. This is repeated multiple times to create a state in which any anti-IL-33 antibody binds to all of the human IL-33 protein molecules on the sensor chip (saturation state), and the amount of binding in the saturated state (saturation binding amount 1) is determined. A similar experiment is also performed with a human anti-IL-33 neutralizing monoclonal antibody comprising an amino acid sequence of a specific combination of amino acid sequences of the complementarity determining regions or a specific combination of amino acid sequences of the variable regions of the present invention, and the amount of binding at saturation (saturation binding amount 2) is determined. Next, the human IL-33 protein on the sensor chip is saturated with a human anti-IL-33 neutralizing monoclonal antibody comprising an amino acid sequence of a specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions of the present invention, and then any anti-IL-33 antibody (15 μg / mL) is loaded as an analyte to examine whether it additionally binds to the human IL-33 protein saturated with the human anti-IL-33 neutralizing monoclonal antibody comprising an amino acid sequence of a specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions of the present invention. When any anti-IL-33 antibody can bind to a human IL-33 protein saturated with a human anti-IL-33 neutralizing monoclonal antibody comprising a specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions of the present invention in an additional manner while exhibiting the saturation binding amount 1 of the any anti-IL-33 antibody calculated above, the antibody is judged to be "non-competitive." On the other hand, when any anti-IL-33 antibody cannot bind to a human IL-33 protein saturated with a human anti-IL-33 neutralizing monoclonal antibody comprising a specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions of the present invention in an additional manner, the antibody is judged to be "competitive." Furthermore, even if any anti-IL-33 antibody can additionally bind to a human IL-33 protein saturated with a human anti-IL-33 neutralizing monoclonal antibody comprising amino acid sequences of a specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions of the present invention, the antibody is deemed to "compete" if the additional binding amount does not reach the saturated binding amount of 1 with a significant difference. The significant difference can be examined by a general testing method (e.g., Student's t-test), and the significance level is 5% or 1% or less.
[0118] The anti-IL-33 neutralizing monoclonal antibody that competes for binding to IL-33 with a human anti-IL-33 neutralizing monoclonal antibody comprising an amino acid sequence of the above-mentioned specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions may be an antibody derived from any animal, such as a mouse antibody, human antibody, rat antibody, rabbit antibody, goat antibody, or camel antibody, or may be a chimeric antibody or humanized antibody that is a combination of these antibodies. The anti-IL-33 neutralizing monoclonal antibody that competes for binding to IL-33 with a human anti-IL-33 neutralizing monoclonal antibody comprising an amino acid sequence of the above-mentioned specific combination of amino acid sequences of complementarity determining regions or a specific combination of amino acid sequences of variable regions is preferably a chimeric antibody, a humanized antibody, or a human antibody, and most preferably a human antibody.
[0119] The anti-IL-33 neutralizing monoclonal antibody that competes with the human anti-IL-33 neutralizing monoclonal antibody in binding to IL-33 and that comprises the above-mentioned specific combination of amino acid sequences of the complementarity determining regions or the specific combination of amino acid sequences of the variable regions includes an antibody fragment. Examples of the antibody fragment include a Fab fragment, an Fv fragment, an F(ab')2 fragment, an Fab' fragment, and an scFv, and an antibody fragment bound to PEG or the like is preferred.
[0120] The method for producing the anti-IL-33 neutralizing monoclonal antibody of the present invention will be described below. By using genetic engineering techniques, a DNA sequence containing a desired combination of complementarity determining regions and a combination of framework regions and also containing a DNA sequence encoding a light chain variable region and a heavy chain variable region can be incorporated into an expression vector, which is transformed into a host cell, and the host cell can be cultured to produce the human anti-IL-33 neutralizing monoclonal antibody of the present invention (see, for example, Borrebaeck CAK and Larrick JW THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). In addition, DNA sequences encoding the constant regions of the light chain and heavy chain can be linked to DNA sequences encoding the heavy chain variable region and the light chain variable region, respectively, to prepare DNA sequences encoding the full-length heavy chain and full-length light chain. The DNA sequences encoding the full-length heavy chain and full-length light chain of the human anti-IL-33 neutralizing monoclonal antibody preferred in the present invention are, for example, IgG1 having a λ chain as the light chain, and are shown in Table 5 below. However, when the antibody is produced using animal cells by genetic engineering techniques, the lysine residue at the C-terminus of the heavy chain may be removed, and the three nucleotides "aag" constituting the 3'-end of the heavy chain nucleic acid sequences shown in Table 5 (SEQ ID NOs: 254 to 277 in the sequence listing) may be removed from each heavy chain nucleic acid sequence:
[0121] [Table 5]
[0122] An in vitro production system can be used as a production system for producing antibodies. Examples of in vitro production systems include production systems using eukaryotic cells, such as animal cells, plant cells, or fungal cells, and production systems using prokaryotic cells, such as bacterial cells such as Escherichia coli and Bacillus subtilis. Examples of animal cells that can be used include mammalian cells, such as commonly used cells such as CHO, COS, myeloma, BHK, HeLa, Vero, 293, NS0, Namalwa, and YB2 / 0, insect cells, and plant cells, with 293 cells and CHO cells being preferred.
[0123] When producing an antibody in an in vitro production system as described above, DNA encoding the heavy and light chains of the antibody may be separately incorporated into an expression vector and then co-transformed into the host, or DNA encoding the heavy and light chains may be incorporated into a single expression vector and then transformed into the host (see International Publication No. WO 94 / 11523).Preferred vectors for use in animal cells include, but are not limited to, pConPlus, pcDM8, pcDNA I / Amp, pcDNA3.1, and pREP4.
[0124] The obtained antibody can be purified to homogeneity. Separation and purification of the antibody can be performed using the separation and purification methods used for ordinary proteins. For example, the antibody can be separated and purified by appropriately selecting and combining a chromatography column such as affinity chromatography, a filter, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, etc. (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988), but is not limited thereto. Examples of columns used for affinity chromatography include protein A columns and protein G columns. For example, examples of protein A columns include Hyper D, POROS, Sepharose FF (Amersham Biosciences), etc.
[0125] Multispecific antibodies such as bispecific antibodies can be prepared by binding an antibody having an antigen-binding specificity other than IL-33 to the human anti-IL-33 neutralizing monoclonal antibody of the present application. Methods for producing bispecific antibodies include well-known chemical methods (Nisonoff, A. et al., Archives of biochemistry and biophysics., 1961, Vol. 90, p. 460-462; Brennan, M. et al., Science, 1985, Vol. 299, p. 81-83). In these methods, first, two types of antibodies are hydrolyzed with an enzyme, and then the disulfide bonds in the heavy chains of the antibodies are cleaved with a reducing agent, and then the different antibodies are mixed and reoxidized to obtain bivalently reactive antibodies. Recently, a preparation method using a crosslinking agent such as glutaraldehyde or carbodiimide has also been disclosed (JP Patent Publication No. 2-1556). Methods for producing multispecific antibodies such as bispecific antibodies by genetic engineering have already been established in this field. For example, the desired bispecific antibodies can be obtained by using the DVD-Ig technology (Wu et al., Nature Biotechnology 25(11), 1290(2007)), which links the antigen-binding regions of two types of monoclonal antibodies in series, or the ART-Ig technology (Kitazawa et al., Nature Medicine 18(10), 1570(2012)), which combines the heavy chains of two types of antibodies that bind to different antigens by modifying the Fc region of the antibody.
[0126] Functionally modified antibodies and conjugate antibodies of human anti-IL-33 neutralizing monoclonal antibodies are prepared by the following methods. For example, when the present human anti-IL-33 neutralizing monoclonal antibody is produced using CHO cells in which the α1,6-fucosyltransferase (FUT8) gene has been disrupted as a host cell, an antibody with a reduced fucose content in the sugar chain and enhanced cell killing function is obtained, and when the antibody is produced using CHO cells in which the FUT8 gene has been introduced as a host cell, an antibody with a reduced cell killing function is obtained (WO 2005 / 035586, WO 2002 / 31140, WO 00 / 61739). In addition, complement activation function can be regulated by modifying amino acid residues in the Fc region (U.S. Patent No. 6,737,056, U.S. Patent No. 7,297,775, U.S. Patent No. 7,317,091). Furthermore, the half-life in blood can be extended by using a mutant Fc region that enhances the binding to FcRn, one of the Fc receptors (Shuhei Hashiguchi et al., Seikagaku, 2010, Vol. 82(8), p. 710; Strohl, Current Opinion in Biotechnology, 2009, vol. 20, p. 685). These functionally modified antibodies can be produced by genetic engineering.
[0127] The human anti-IL-33 neutralizing monoclonal antibody of the present invention can be bound to other functional molecules to prepare a conjugate antibody. For example, when PEG is bound to an antibody as a functional molecule, the PEG that can be used has a molecular weight of, but is not limited to, 2000 to 100,000 Da, more preferably 10,000 to 50,000 Da, and may be either linear or branched. PEG can be bound to the N-terminal amino group of an amino acid of an antibody, for example, by using an NHS active group. When a radioactive substance is used as a functional molecule, 131 I, 125 I, 90 Y, 64 Cu, 99 Tc, 77 Lu or 211Radioactive substances can be directly bound to antibodies by the chloramine T method or the like. When toxins are used as functional molecules, bacterial toxins (e.g., diphtheria toxin), plant toxins (e.g., ricin), low molecular weight toxins (e.g., geldanamycin), maytansinoids, calicheamicin, and the like are used. When low molecular weight compounds are used as functional molecules, examples include daunomycin, doxorubicin, metronexate, mitomycin, neocarzinostatin, vindesine, and fluorescent dyes such as FITC. When an enzyme is used as a functional molecule, luciferase (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), malate dehydrogenase, urease, peroxidase (e.g., horseradish peroxidase (HRPO)), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidase (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidase (e.g., uricase and xanthine oxidase), lactoperoxidase, microperoxidase, etc. are used. Linkers used when chemically binding toxins, low molecular weight compounds, or enzymes include divalent radicals (e.g., alkylene, arylene, heteroarylene), -(CR2) n O(CR2) nExamples of the linker include repeating units of linkers and alkoxy (e.g., polyethyleneoxy, PEG, polymethyleneoxy, etc.) represented by - (R is an arbitrary substituent), alkylamino (e.g., polyethyleneamino, Jeffamine™), and diacid esters and amides (succinate, succinamide, diglycolate, malonate, caproamide, etc.). Chemical modification methods for binding functional molecules have already been established in this field (DJKing., Applications and Engineering of Monoclonal antibodies., 1998 TJ International Ltd, Monoclonal Antibody-Based Therapy of Cancer., 1998 Marcel Dekker Inc; Chari et al., Cancer Res., 1992 Vol152:127; Liu et al., Proc Natl Acad Sci USA., 1996 Vol 93:8681).
[0128] The anti-IL-33 neutralizing monoclonal antibody that competes for binding to IL-33 with the human anti-IL-33 neutralizing monoclonal antibody comprising a specific combination of amino acid sequences of the complementarity determining regions of the present invention (C1, C8, C15, C17, or C18 in Table 1) or a specific combination of amino acid sequences of the variable regions of the present invention (V1, V8, V15, V17, or V18 in Table 2) may be an antibody derived from any animal, such as a mouse antibody, human antibody, rat antibody, rabbit antibody, goat antibody, or camel antibody, or may be a chimeric antibody or humanized antibody that is a combination of these antibodies. These anti-IL-33 neutralizing monoclonal antibodies can be obtained using any known method, such as genetic engineering methods such as the hybridoma method and the phage display method, and are particularly preferably obtained by genetic engineering methods.
[0129] Chimeric antibodies can be obtained by linking DNA encoding the variable region of a non-human antibody to DNA encoding the constant region of a human antibody, incorporating this into an expression vector, and transforming host cells to produce the antibody (see European Publication No. 125023 and International Publication No. WO 92 / 19759).
[0130] Humanized antibodies can be obtained by linking DNA encoding the complementarity determining regions of a non-human antibody to the remaining human antibody regions, incorporating this into an expression vector, and introducing it into a host for production.
[0131] Human antibodies are prepared, for example, using the procedures described in the Examples provided below. Human antibodies can also be prepared using trioma technology, human B-cell hybridoma technology (Kozbor et al., 1983 Immunol Today 4: p72), and EBV hybridoma technology for producing human monoclonal antibodies (Cole et al., 1985, MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., p. 77), etc. Furthermore, human antibodies can also be produced by immunizing a transgenic mouse into which a human antibody gene has been introduced with an antigen protein to produce a hybridoma. Examples of transgenic mice include HuMab® mice (Medarex), KMTM mice (Kirin Pharma), KM (FCγRIIb-KO) mice, VelocImmune mice (Regeneron), etc.
[0132] Another embodiment of the present invention is an artificial antibody that competes with a human anti-IL-33 neutralizing monoclonal antibody that contains a combination of specific amino acid sequences of the complementarity determining regions of the present invention (C1, C8, C15, C17, or C18 in Table 1) or a combination of specific amino acid sequences of the variable regions of the present invention (V1, V8, V15, V17, or V18 in Table 2) in binding to IL-33. For example, the tenth unit (FNfn10) of the human fibronectin type III domain can be used as an artificial antibody, and an artificial antibody that binds to a desired target can be obtained by introducing mutations into the BC, DE, and / or FG loop of the unit. In addition to the extracellular domain of fibronectin, the artificial antibody can be a Kunitz domain of a serine protease inhibitor, or a peptide such as ankyrin or lipocalin. These artificial antibodies can be produced by genetic engineering by introducing a vector containing a nucleic acid molecule encoding the peptide into Escherichia coli, yeast, animal cells, or the like, and purifying the peptide from the culture supernatant of the host cells.
[0133] As an artificial antibody, instead of using the amino acid sequence of a specific protein or a part thereof as described above, it is also possible to search for a low molecular weight peptide molecule that specifically binds to the epitope of the present invention like an antibody from a random sequence library in which amino acids are randomly combined (e.g., Hipolito et al., Current Opinion in Chemical Biology, 2012 Vol. 16: 196, Yamagishi et al., Chemistry & Biology, 2011 Vol. 18: 1562). Such peptides can be produced by chemical synthesis methods such as the fluorenylmethyloxycarbonyl method and the t-butyloxycarbonyl method, in addition to genetic engineering methods.
[0134] [Antibody sequence combination] C1 to C30 in Table 1, which are combinations of amino acid sequences of the complementarity determining regions of the human anti-IL-33 neutralizing monoclonal antibody described in the present application, V1 to V30 in Table 2, which are combinations of amino acid sequences of the variable regions, CN1 to CN30 in Table 5, which are combinations of nucleic acid sequences of the complementarity determining regions, and IGN1 to IGN30 in Table 5, which are combinations of nucleic acid sequences of the antibodies, each correspond to the sequence of the same clone, and the correspondence is shown in Table 6 below. For example, the amino acid sequence of the complementarity determining region of clone A10-1C04 is a combination of the six amino acid sequences of the complementarity determining region of C1, and this combination of amino acid sequences of the complementarity determining regions can be encoded by the six nucleic acid sequences of CN1. In addition, the amino acid sequences of the heavy and light chain variable regions of this clone are the two amino acid sequences of V1, and the amino acid sequences of the λ light chain and the γ heavy chain including the variable region of V1 are encoded by the two nucleic acid sequences of IGN1.
[0135] [Table 6] EXAMPLES
[0136] The present invention will be described in detail below with reference to examples. However, unless otherwise specified, the present invention is not limited to the following.
[0137] Example 1: Obtaining anti-IL-33 antibodies and identifying epitope peptides [Obtaining antibodies] Monoclonal antibodies were obtained by immunizing animals with human IL-33 protein and producing hybridomas from the spleen cells of the immunized animals. Antibodies that bind to human IL-33 protein were cloned by phage display technology from an animal antibody library produced using RNA collected from the spleen cells of the immunized animals and from a human naive antibody library. In this way, eight types of anti-IL-33 monoclonal antibodies (antibodies A to H) were obtained.
[0138] [Peptide array scan] To identify the epitope of the obtained IL-33 antibody, a peptide array scan was performed to examine the binding between partial peptides (20 residues long) of human IL-33 and each antibody. A total of 16 types of 20-amino acid-long peptides (PEP11 to PEP26) were synthesized, shifting the starting position by 10 amino acids from the N-terminus in the range from valine at position 101 (V101) to threonine at position 270 (T270), so as to cover the main mature human IL-33 molecule. The sequences and positional relationship of these peptides are shown in Table 7.
[0139] [Table 7]
[0140] Each peptide with its N-terminus biotinylated was immobilized as a ligand on a neutravidin sensor chip of a Surface Plasmon Resonance (SPR) device (Bio-Rad, ProteOn XPR36). As a positive control, an avitag sequence was added to the N-terminus of mature human IL-33 (residues 112 to 270), and the protein (hIL-33) was biotinylated specifically to the avitag sequence by biotin ligase reaction and immobilized as a ligand on the SPR sensor chip. The ligand-immobilized sensor chip was subjected to flow of the test antibody, human IL-33 receptor protein (recombinant human ST2 Fc chimera) (Enzo Life Science, ALX-201-367-C050) or buffer (0.05% Tween20 / PBS) alone (antibody concentration: 10 μg / ml; flow rate: 100 μl / min) as an analyte to bind to the ligand on the sensor chip after washing, and the amount of analyte (antibody amount) bound to the ligand on the sensor chip was shown as an RU value. The results are shown in Figure 2.
[0141] In order from the antibodies with epitopes on the N-terminus of human IL-33 protein, antibody A and antibody B bound to PEP12. Antibody C and antibody D bound to PEP14. Antibody E bound to both PEP16 and PEP17. Antibody F bound to PEP24. Antibody G and antibody H bound to PEP26. A commercially available anti-human IL-33 polyclonal antibody (R&D Systems, AF3625) bound to most of the 16 types of human IL-33 peptides used in the study. On the other hand, the human IL-33 receptor (ST2) bound to the human IL-33 protein, but hardly bound to the human IL-33 peptides (PEP11 to PEP26), and this test did not reveal which part of IL-33 is important for binding to ST2. In addition, no binding to the ligand was observed with buffer alone or mouse IgG (R&D Systems, MAB002). When the binding affinity to hIL-33 (residues 112 to 270) was compared among the antibodies used, the order of strongest binding to hIL-33 (residues 112 to 270) was antibody G, antibody H, antibody D, antibody E, antibody B, antibody A, antibody C, and antibody F.
[0142] Example 2: Evaluation of IL-33 neutralizing activity of anti-IL-33 monoclonal antibodies-1 The IL-33 neutralizing activity of antibodies A, B, E, and F was measured using the inhibitory effect on the binding of solid-phase human ST2 to human IL-33 as an index. Recombinant human ST2 Fc chimera (Enzo Life Science, ALX-201-367-C050) (1 μg / mL, 50 μL / well) diluted with phosphate-buffered saline (PBS) was dispensed into a 96-well microplate (NuncTM, #442404) and left to stand overnight at 4°C. The next day, the plate was washed once with PBS containing 1% BSA (PBS-B), and the same solution (250 μL / well) was added and blocked at room temperature for 2 hours. Then, a mixture (50 μL / well) of the test antibody (final concentration 10 μg / mL) and recombinant human IL-33 protein (ATGen, ILC0701) (final concentration 1 μg / mL) diluted with PBS-B was added and incubated at room temperature for 2 hours. After washing the microplate five times with PBS containing 0.1% Tween 20 (PBS-T), goat anti-human IL-33 antibody (R&D Systems: AF3625, final concentration 1 μg / mL, 50 μL / well) diluted with PBS-B was added and incubated at room temperature for 1 hour. After washing the microplate five times with PBS-T, HRP-labeled rabbit anti-goat IgG antibody (Invitrogen: 61-1620, 50 μL / well) diluted 2000-fold with PBS-B was added and incubated at room temperature for 1 hour. After washing the microplate five times with PBS-T, SureBlueTM TMB Microwell Peroxidase Substrate (KPL: 52-00-01, 50 μL / well) was added and reacted at room temperature for 20 minutes. The reaction was stopped with TMB Stop Solution (KPL: 50-85-05, 50 μL / well), and the difference in absorbance at wavelengths of 450 nm and 620 nm was measured using a plate reader (SPECTRA MAX 190, Molecular Devices). The inhibitory effect of the antibody on the binding of ST2 and IL-33 (IL-33 / ST2 binding system competitive inhibition rate) was calculated by using a sample containing human IL-1β (PeproTech, 200-01B) (final concentration 1 μg / mL) instead of human IL-33 as the background, and calculating the inhibition rate (%) relative to a sample containing human IL-33 (final concentration 1 μg / mL) alone.As a result, antibody A (epitope is PEP12) showed 66% inhibition, antibody B (epitope is PEP12) showed 55% inhibition, antibody E (epitope is PEP16-17) showed 0% inhibition, and antibody F (epitope is PEP24) showed 39% inhibition. Of the four antibodies examined, all antibodies (antibody A, antibody B, antibody F) except for antibody E showed an inhibition rate of 30% or more at a final concentration of 10 μg / mL.
[0143] [Table 8]
[0144] Example 3: Evaluation of IL-33 neutralizing activity of anti-IL-33 monoclonal antibodies-2 The IL-33 neutralizing activity of the test antibodies (Antibodies A to H) was measured using the inhibitory effect on human IL-33-induced IL-6 production in normal human umbilical vein endothelial cells (HUVEC) (LONZA, CLC2517A) as an index. HUVEC were seeded (6 × 10 3 / 0.1mL / well) and confirm that the cells were confluent. Anti-IL-33 antibody (final concentration 10μg / mL) and recombinant human IL-33 (ATGen, ILC0701, final concentration 100ng / mL) were added to the medium (EGM-2 medium (LONZA, CLCC-3156, CLCC-4176)) (0.2mL / well) and incubated at 37℃ for 24 hours. After 24 hours, the IL-6 concentration in the medium was measured using a commercially available ELISA kit (Thermo Scientific, EH2IL6). In addition, the cell viability at the time of medium collection was measured using a cell counting kit (Dojindo, 345-06463), and it was confirmed that the inhibitory effect on IL-6 production was not due to a decrease in the number of viable cells. The IL-33 neutralizing activity of the test antibody (HUVEC IL-6 production inhibition rate) was calculated as the inhibition rate (%) of IL-6 production by recombinant human IL-33 treatment alone. As a result, antibody A (epitope is PEP12) showed 51% inhibition, antibody B (epitope is PEP12) showed 48% inhibition, antibody C (epitope is PEP14) showed 33% inhibition, antibody D (epitope is PEP14) showed 38% inhibition, antibody E (epitope is PEP16-17) showed 0% inhibition, antibody F (epitope is PEP24) showed 38% inhibition, antibody G (epitope is PEP26) showed 48% inhibition, and antibody H (epitope is PEP26) showed 56% inhibition. Of the eight antibodies, all antibodies except antibody E showed an inhibition rate of 30% or more (Table 9). Among these antibodies, antibodies that bind to epitopes selected from the group consisting of positions 111 to 130, 131 to 150, 231 to 250, and 251 to 270 of SEQ ID NO: 1 showed a large increase in neutralizing activity when the antibody concentrations were set to 3, 10, and 30 μg / mL (for example, 23, 42, and 61% inhibition, respectively, for antibody D), and were found to be suitable epitopes for generating antibodies with antagonistic activity.
[0145] [Table 9]
[0146] Although antibody E binds to hIL-33 (FIG. 2), it did not show functional neutralizing ability (Tables 8 and 9). Patent Document 2 (WO2008 / 132709) describes three types of epitopes, epitope 1 (positions 155-198), epitope 2 (positions 165-188), and epitope 3 (positions 175-178), but it was revealed that these epitopes overlap with the epitope peptide (positions 151-180) of antibody E, which was confirmed to have no neutralizing activity for IL-33. From these results, it was considered that the antibody against the epitope in Patent Document 2 cannot sufficiently inhibit the binding of IL-33 to its receptor ST2, and has no neutralizing activity for IL-33, or if it does have such activity, it has a very low neutralizing activity.
[0147] Theoretically, the reason why antibody E did not show neutralizing activity for IL-33 may be due to insufficient affinity, in addition to the superiority or inferiority of the epitope. However, this possibility is considered to be low due to the existence of clones such as antibody D, antibody G, and antibody H, which showed clear neutralizing activity for IL-33, despite tending to bind hIL-33 weaker than antibody E. From these facts, when the purpose is to neutralize the cytokine IL-33, the epitope described in Patent Document 2 is an epitope in which binding to IL-33 and neutralizing activity for IL-33 are not related, whereas the four epitopes we found this time (PEP12, PEP14, PEP24, PEP26) are considered to be functional epitopes in which binding to IL-33 and neutralizing activity for IL-33 are related. Antibodies that bind to functional epitopes have a high antagonistic effect against IL-33, while antibodies that bind to non-functional epitopes are considered to have a low or no antagonistic effect against IL-33.
[0148] Example 4: Mapping of epitope peptides onto the human IL-33 conformation In order to identify the interface atoms (IL-33 atoms within 5 Å of the ST2 atoms) that are preferred epitopes for generating antibodies with antagonistic activity, the epitope peptides were mapped onto the three-dimensional structure of the human IL-33-human ST2 complex. The X-ray crystal structure of the human IL-33-human ST2 complex (Research Collaboratory for Structual Bioinformatics: PDB ID 4KC3) lacked a portion of the IL-33 protein structure, so the positions of all the epitope peptides identified in this study could not be shown. Therefore, a homology model was created using the X-ray crystal structure (4KC3) as a template (Figure 3, using Accelrys Discovery Studio 3.5), and the epitope peptides (PEP12, PEP14, PEP24, PEP26) of the antibodies that showed neutralizing activity in this study were mapped (Figures 4-7). In Figures 4 to 7, human IL-33 and the epitope peptides are shown in dark gray, and ST2, which binds to them, is shown in light gray. To clearly show the position of the contact surface with the receptor on the IL-33 protein surface, the interface atoms are highlighted with large spheres. As a result, it was found that these epitope peptides (PEP12, PEP14, PEP24, PEP26) each have amino acids that include interface atoms. Examples of amino acids containing interface atoms include P118, I119, T120, Y122, L123, R124, S125, L126, S127, Y129, and N130 of PEP12, D131, Q132, S133, T135, A137, L138, E139, S142, Y143, E144, I145, Y146, E148, D149, and L150 of PEP14, D244, N245, and H246 of PEP24, and K266, L267, S268, and E269 of PEP26. As an epitope to which an antibody having an antagonistic effect specifically binds, an epitope having an amino acid containing an interface atom is considered to be preferable.
[0149] Example 5: Obtaining human anti-IL-33 antibody (parent clone) Using a human scFv phage display library (BioInvent, n-CoDeR) (Soderlind et al., Nature biotechnology, 2000 Vol.18(8), p852), two parent clones (scFv) (meaning that the molecular form is scFv, hereinafter the same) were obtained that bind to mature IL-33 (residues 112 to 270), inhibit the binding of IL-33 to ST2, and inhibit the activity of IL-33 using the IL-33-dependent IL-6 production in normal human umbilical vein endothelial cells (HUVEC) described below as an indicator (clone names: A00-0070 and A00-0036). The nucleotide sequences of these antibodies were determined, and the amino acid sequences of the light chain and heavy chain variable regions were determined. The combinations of the amino acid sequences of the light chain and heavy chain variable regions of A00-0070 and A00-0036 were V29 and V30 in Table 2, respectively.
[0150] Example 6: Determining Amino Acid Substitutions to Improve Complementarity Determining Regions To improve the affinity of the two parent clones for IL-33 and their physical properties (reducing aggregation by reducing surface hydrophobicity and improving solubility), we modified the complementarity-determining regions by Fab ribosome display and Fab phage display. The improvement of the complementarity-determining regions was carried out in two stages. In the first stage, we determined single amino acid substitutions that could improve the affinity for IL-33 and the physical properties, and in the second stage, we determined multiple combinations of these single amino acid substitutions (Fujino et al., Biochem. Biophys. Res. Commun., 2012 Vol. 428(3), p395).
[0151] A Fab ribosome display vector was constructed using the light and heavy chain variable regions of the two parent clones. Using this vector as a template, a comprehensive library of single amino acid substitution mutants was constructed by substituting all amino acid residues constituting the six antibody complementarity determining regions (LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3) with natural amino acids, totaling 20 types, one by one. Using the Fab ribosome display method (Fujino et al., Biochem. Biophys. Res. Commun., 2012 Vol. 428(3), p395) with the reconstituted cell-free translation system PURE system (Genefrontier, PUREfrex) (Shimizu et al., Nature Biotechnology, , 2001Vol. 19(8), p751), a comprehensive library of single amino acid substitution mutants was enriched several times using recombinant human IL-33 protein (ATGen, ILC0701) as bait. The nucleotide sequences of the light and heavy chain variable regions of each clone (Fab) (meaning that the molecular form is Fab, hereafter the same) contained in the library before enrichment (immediately after construction) and after enrichment were determined using a next-generation sequencer (Roche, 454). Sequence data of several thousand reads were obtained from each library before and after enrichment, and the frequency of all single amino acid substitution mutants in the complementarity determining regions was calculated. Next, the fold change in the frequency of all single amino acid substitution mutants in the library before and after enrichment (enrichment ratio) was calculated, and single amino acid substitutions that are considered to be useful for improving affinity for human IL-33 protein were selected using the magnitude of the enrichment ratio due to library enrichment as an index. Furthermore, taking into consideration the total number of these single amino acid substitutions and their distribution on the amino acid sequence, the positions for introducing amino acid substitutions in the custom library to be constructed in the second stage were determined.
[0152] In the parent clone A00-0070, it was decided to introduce amino acid substitutions at the 12th asparagine of LCDR1 (sequence number 2 in the sequence listing), the 4th glutamine of LCDR2 (sequence number 11 in the sequence listing), the 2nd serine, the 3rd tyrosine, and the 6th serine of LCDR3 (sequence number 23 in the sequence listing), the 1st aspartic acid and the 5th asparagine of HCDR1 (sequence number 43 in the sequence listing), and the 4th serine, the 5th serine, the 7th serine, and the 9th isoleucine of HCDR2 (sequence number 64 in the sequence listing). In the parent clone A00-0036, it was decided to introduce amino acid substitutions into the 9th asparagine and the 13th asparagine of LCDR1 (SEQ ID NO: 6 in the Sequence Listing), the 6th arginine and the 7th leucine of LCDR2 (SEQ ID NO: 20 in the Sequence Listing), the 1st alanine, the 9th alanine and the 10th valine of LCDR3 (SEQ ID NO: 40 in the Sequence Listing), the 1st asparagine of HCDR1 (SEQ ID NO: 47 in the Sequence Listing), the 4th serine, the 5th serine, the 6th serine, the 7th serine, the 8th tyrosine, the 9th isoleucine, the 10th tyrosine, the 11th tyrosine, the 13th aspartic acid and the 16th lysine of HCDR2 (SEQ ID NO: 64 in the Sequence Listing), and the 2nd glycine, the 5th histidine and the 6th aspartic acid of HCDR3 (SEQ ID NO: 78 in the Sequence Listing).
[0153] To improve the physical properties, a homology model of two parent clones was created using a protein structure analysis program (Accelrys, Discovery Studio), and regions with high surface hydrophobicity were predicted in the complementarity determining regions. Next, to reduce the surface hydrophobicity of such regions, it was decided to introduce amino acid substitutions into the third tyrosine of LCDR3 (SEQ ID NO: 23 in the sequence listing), the seventh serine, and the ninth isoleucine of HCDR2 (SEQ ID NO: 64 in the sequence listing) in parent clone A00-0070, and into the sixth arginine and seventh leucine of LCDR2 (SEQ ID NO: 20 in the sequence listing), the seventh serine, the eighth tyrosine, and the ninth isoleucine of HCDR2 (SEQ ID NO: 64 in the sequence listing) in parent clone A00-0036. Amino acid substitutions that are considered to be useful for reducing surface hydrophobicity while maintaining the binding ability to human IL-33 protein at these sites were determined in consideration of the enrichment ratio data in the mutation analysis using a comprehensive single amino acid substitution mutant library.
[0154] Example 7: Creation of human anti-IL-33 antibodies with improved complementarity determining regions A custom library for improving the complementarity-determining regions was designed by combining multiple useful amino acid substitutions described above aimed at improving affinity and physical properties. Fab ribosome display and Fab phage display vectors were constructed, and multi-step PCR reactions using site-directed mutagenesis PCR and overlap extension PCR with the Fab ribosome display vector as a template, and site-directed mutagenesis by the Kunkel method with the Fab phage display vector as a template (Fellouse et al., J. Mol. Biol. 2007 Vol. 373, p924) were performed to construct a custom library for improving the complementarity-determining regions in which the complementarity-determining regions were randomized based on the above design. Using human IL-33 protein and cynomolgus monkey IL-33 protein (GenBank: EHH57404, from Ser at residue 112 to Glu at residue 269 of SEQ ID NO: 227 in the sequence listing) as bait, several rounds of library enrichment by Fab ribosome display and Fab phage display were repeated. In the later rounds, negative selection was performed using hydrophobic column supports such as Octyl Sepharose (GE Healthcare) or Phenyl Sepharose (GE Healthcare) before binding to IL-33 protein to enrich for Fabs with high affinity for IL-33 protein and low surface hydrophobicity. The recombinant proteins used as bait were prepared as follows. Mature human IL-33 (residues 112 to 270) and mature cynomolgus IL-33 (residues 112 to 269 of SEQ ID NO: 227 in the Sequence Listing) were added with 6His tag-Avi tag on the N-terminus and inserted into pET30a(-) to construct expression vectors, and recombinant proteins were prepared. E. coli BL21(DE3) strain carrying the expression vector was precultured in 5 mL of LB medium, and 1 mL of the preculture was inoculated into 50 mL of expression medium (Merck, Overnight Express; kanamycin added), and expression culture was performed at 30°C / 200 rpm for approximately 18 hours. The collected cells were washed and then lysed with BagBuster (Novagen), and the supernatant was collected. The 6His-tag-Avi-tag-cynomolgus IL33 (residues 112 to 269) contained in the supernatant was purified using Ni-NTA Agarose (QIAGEN), and biotin modification was introduced specifically to the Avi-tag portion using a commercially available biotin ligase (Avidity, BirA).
[0155] Using the enriched library, an E. coli library secreting and expressing Fab was constructed, and the dissociation rate constant (koff) was measured by surface plasmon resonance (SPR) using culture supernatants of several hundred E. coli clones (Bio-Rad, ProteOn XPR36). The biotinylated human IL-33 protein (4 μg / mL) and the cynomolgus monkey IL-33 protein (4 μg / mL) were loaded as ligands onto a sensor chip (Bio-Rad, NLC sensor chip), and 1300 to 1600 RU of human IL-33 protein and 1100 to 1500 RU of cynomolgus monkey IL-33 protein were immobilized. Next, the E. coli culture supernatant was loaded as an analyte, and a sensorgram was obtained for the binding phase of 1 minute and the dissociation phase of 10 to 30 minutes. Interspot correction and blank correction of the sensorgram were performed using an SPR data analysis program (Bio-Rad, ProteOn Manager v3.1.0), and koff was calculated by Langmuir off-rate analysis.
[0156] Among the clones (Fab) with improved complementarity determining regions, clones with improved affinity for human IL-33 protein and binding ability to cynomolgus monkey IL-33 protein were selected as 28 clones to be advanced to higher evaluation in Example 8 and thereafter (V1 to V28 in Table 2). As shown in Table 10, these clones (Fab) showed higher affinity (lower Koff value) for human and cynomolgus monkey IL-33 protein compared to the parent clone (Fab). There were no amino acid substitutions in the framework regions of the variable regions of these clones. Even with the same single amino acid substitution in the complementarity determining region, the affinity improving effect differs between single amino acid substitution mutants and multiple amino acid substitution mutants, so there were amino acid substitutions that were frequent in the sequences of the 28 clones for higher evaluation despite the low enrichment ratio from the comprehensive single amino acid substitution mutant library in the first stage, and conversely, amino acid substitutions that were frequent in the sequences of the 28 clones for higher evaluation despite the high enrichment ratio in the first stage.
[0157] [Table 10]
[0158] Example 8: Preparation of IgG antibodies For the seven clones of human anti-IL-33 antibodies obtained (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02, A00-0070, A00-0036), DNA encoding the amino acid sequences of the light and heavy chains was inserted downstream of the CMV promoter to construct an expression vector for mammalian cells expressing IgG. The DNA sequences of the light chains of each clone were SEQ ID NOs: 228, 232, 239, 241, 242, 230, and 253 in the sequence listing, respectively, and the DNA sequences of the heavy chains were SEQ ID NOs: 254, 261, 262, 264, 265, 276, and 277 in the sequence listing, respectively. The expression vector was introduced into FreeStyle 293-F cells (Life Technologies) using a gene introduction reagent NeoFection-293-1 (Astec). After 5 days of culturing after gene introduction, the culture supernatant was obtained. Stable expression lines in CHO cells were established using the pConPlus vector and CHO K1SV cells in the GS system (Lonza). The stable expression lines in CHO cells were established using a WAVE Bioreactor SYSTEM 20 / 50 EHT (GE Healthcare) at 0.3 × 10 6 Culture was started from 100 cells / mL, and the culture medium containing secreted IgG was collected. IgG was purified from the culture supernatant by affinity chromatography using Protein A resin (GE Healthcare, HiTrap MabSelect SuRe) using AKTA explorer 100 (GE Healthcare). IgG bound to Protein A resin was eluted with an elution buffer of pH 3.2, and the pH was quickly neutralized to near neutral, and then dialyzed against PBS (pH 7.2). In order to increase the purification purity, the IgG after Protein A column purification was purified with CHT (ceramic hydroxyapatite Type I resin) (BIORAD). IgG bound to CHT was eluted with a gradient of NaCl concentration, and the desired fraction was collected and dialyzed against PBS (pH 7.2). The antibody obtained by this purification method was called "neutral purified antibody". A purification method was also performed in which a washing step for 6 minutes with 6 column volumes of 100 mM sodium carbonate buffer (pH 11.0) was added before the elution step from the Protein A resin in the above purification method. The antibody obtained by this purification method was named "alkaline purified antibody." The recovery rate of the alkaline purified antibody at each step is shown in Table 11. After purification, the alkaline purified antibody was concentrated by centrifugation using a VIVASPIN Turbo15 30000MWCO (Sartoeius).
[0159] [Table 11]
[0160] Example 9: Affinity for IL-33 protein The affinity of the test antibody (IgG) (meaning that the molecular form is IgG, hereafter referred to as such) to human IL-33 protein was determined by measuring the dissociation constant (Kd) in PBS using a kinetic exclusion assay (KinExA) (Sapidyne, KinExA3200). Mixed samples were prepared by titrating human IL-33 protein (ATGen, ILC0701) over a wide range of concentrations (2048-fold concentration range with the upper limit of the final concentration being several nM to several tens of nM) against the test antibody at a fixed concentration (final concentration of several tens of pM to several hundreds of pM), and incubated at room temperature until the antigen-antibody reaction reached equilibrium. After equilibrium was reached, the presence rate of free anti-IL-33 antibody was measured using KinExA3200. Using the KinExA data analysis program (Sapidyne, KinExA Pro Software v3.5.3), Kd was calculated by fitting a plot of the percentage of anti-IL-33 antibodies not bound to human IL-33 protein (vertical axis) and the antigen concentration (horizontal axis) to a theoretical equation. Anti-IL-33 antibody capture beads were prepared by suspending 50 mg of Azlactone beads (Sapidyne) in 1 mL of coating solution (10 μg / mL human IL-33 protein (ATGen, ILC0701), 50 mM sodium carbonate pH 9.6) and incubating at room temperature for 1 hour. Anti-human F(ab)'2-DyLight649 (Jackson, 309-495-006) was used as the detection antibody. As shown in Table 12, when neutral purified antibodies were used, the affinities of antibodies with improved complementarity-determining regions (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) for human IL-33 protein were the weakest (A23-1A05, Kd = 231 pM) and the strongest (A25-2C02, Kd = 720 fM).
[0161] Similarly, the affinity of the alkali-purified antibodies for human IL-33 protein (residues 112-270) (ATGen, ILC0701) or full-length human IL-33 protein was measured by KinExA (Table 12). The affinity for human IL-33 protein (residues 112-270) was Kd = 100.3 pM for A10-1C04, Kd = 195.3 pM for A23-1A05, Kd = 700 fM for A25-2C02, Kd = 7.7 pM for A25-3H04, and Kd = 5.3 pM for A26-1F02. The affinity for full-length human IL-33 protein was Kd = 179.8 pM for A10-1C04 and Kd = 10.4 pM for A26-1F02.
[0162] The recombinant protein used as the ligand was prepared as follows. The full-length human IL-33 protein was prepared by constructing an expression vector by inserting a NusA tag-6His tag-TEV Protease cleavage sequence added to the N-terminus side into pET30a(+). After pre-culture, the BL21(DE3) strain carrying the expression vector was inoculated into 50 mL of LB medium at a density of OD=0.5 and cultured at 37°C for 4 hours with shaking. After 4 hours, the culture temperature was changed to 13°C and cultured with shaking for 30 minutes, IPTG was added to a final concentration of 0.1 mM, and the culture was continued at 13°C for 72 hours with shaking to obtain full-length IL-33-expressing E. coli. The full-length IL-33-expressing E. coli was lysed with BugBuster Master Mix (Novagen), and centrifuged to obtain the supernatant fraction. The collected supernatant was subjected to IMAC purification using a HisTrap FF Crude column (GE Healthcare) and anion exchange purification using a CaptoQ Impress column (GE Healthcare) to increase protein purity. The sample after anion exchange was centrifuged and concentrated by ultrafiltration using a VIVASPIN6 (5,000 MWCO). NusTag and HisTag were cleaved by adding 100 μL of Turbo TEV protease (Nacalai Tesque) and 4.5 μL of 1M DTT to 1750 μL of the concentrated solution and incubating at 4 °C. After tag cleavage, the sample was subjected to a Ni Sepharose Excel column (GE Healthcare) to remove NusTag and Turbo TEV protease (HisTag fusion) contained in the sample, and the flow-through fraction was collected. DTT was added to the flow-through fraction to a final concentration of 3.3 mM, and the full-length human IL-33 protein was used for measurement with KinExA.
[0163] [Table 12]
[0164] Example 10: Evaluation of neutralizing activity of human IL-33 in vitro using HUVEC The in vitro neutralizing activity of the test antibody (IgG) against human IL-33 was evaluated using IL-33-dependent IL-6 production by HUVEC as an index. A commercially available polyclonal anti-IL-33 antibody (R&D Systems, AF3625) was used as a positive control. HUVEC (LONZA, CLC2517A) were suspended in EGM-2 medium (LONZA, CLCC-3156, CLCC-4176) and seeded (6x10 3 The medium was incubated at 37°C for 24 hours. The medium was then collected and the IL-6 concentration in the culture supernatant was measured using a commercially available ELISA kit (Thermo Scientific, EH2IL6). The cell viability at the time of collection was measured using a cell counting kit (Dojindo, 345-06463), and it was confirmed that the inhibitory effect on IL-6 production was not due to a decrease in the number of viable cells. The IL-33 neutralizing activity of the test antibody was calculated as the inhibition rate (%) of IL-6 production by IL-33 treatment alone. When neutral purified antibodies were used, A10-1C04 showed 67% inhibition, A23-1A05 showed 74% inhibition, A25-2C02 showed 96% inhibition, A25-3H04 showed 97% inhibition, and A26-1F02 showed 96% inhibition, showing strong neutralizing activity, whereas the parent clones A00-0070 and A00-0036 showed very weak neutralizing activity, with 4% and -2%, respectively. By increasing the concentration to 10 μg / mL, A00-0070 and A00-0036 showed moderate neutralizing activity, with 42% and 38%, respectively. On the other hand, a commercially available polyclonal antibody (R&D Systems, AF3625) showed moderate neutralizing activity, with 30% inhibition, when added at a final concentration of 1 μg / mL. Similarly, a mixture of alkali-purified test antibodies (final concentration 0.1-10 μg / mL (approximately 0.67-67 nM)) and recombinant human IL-33 (ATGen, ILC0701) (final concentration 100 ng / mL (approximately 5 nM)) was added to HUVECs, and the neutralizing activity of the antibodies was evaluated for their inhibitory effect on IL-6 production by treatment with IL-33 alone (IC 50 A10-1C04 is IC 50 = 0.35μg / mL, A23-1A05 is IC 50 = 0.27μg / mL, A25-2C02 is IC 50 = 0.19μg / mL, A25-3H04 is IC 50 = 0.21μg / mL, A26-1F02 was IC 50 =0.23μg / mL. In addition, a mixture of alkali-purified test antibodies (final concentration 0.1 to 3 μg / mL) and recombinant cynomolgus monkey IL-33 (prepared by the method described in Example 7 and used without biotinylation) (final concentration 100 ng / mL) was added to HUVEC, and the neutralizing activity of the antibodies was evaluated as the inhibitory effect (IC) on IL-6 production by treatment with IL-33 alone. 50 The IC value of A10-1C04 was calculated. 50 The neutralization potency of A10-1C04 was 0.43 μg / mL, confirming that A10-1C04 neutralized human IL-33 and cynomolgus monkey IL-33 with similar potency.
[0165] Example 11: Evaluation of neutralizing activity of human IL-33 in vitro using KU-812 cells The in vitro neutralizing activity of the test antibody (IgG) against human IL-33 was evaluated using the IL-33-dependent production of IL-5, IL-6, and IL-13 by KU-812 cells as an index. A commercially available polyclonal anti-IL-33 antibody (R&D Systems, AF3625) was used as a positive control. Human basophil cell line, KU-812 cells (ECACC, EC90071807), were seeded (1x10 4 / well). Then, a mixture of the test antibody (final concentration 3 μg / mL (approximately 20 nM)) and recombinant human IL-33 (ATGen, ILC0701) (final concentration 100 ng / mL (approximately 5 nM)) was added and incubated at 37°C for 24 hours. The concentrations of IL-5, IL-6, and IL-13 in RPMI-1640 medium containing 10% FBS were measured using the Human IL-5 Flex set, Human IL-6 Flex set, and Human IL-13 Flex set of BDTM Cytometric Bead Array (BD Biosciences). In addition, the viability of cells at the time of medium collection was measured using a cell counting kit (Dojindo, 345-06463), and it was confirmed that the inhibitory effect on the production of IL-5, IL-6, and IL-13 was not due to a decrease in the number of viable cells. When neutral purified antibodies were used in this evaluation system, A26-1F02 inhibited the production of IL-5, IL-6, and IL-13 by 70%, 82%, and 72%, respectively, demonstrating stronger neutralizing activity against the production of each cytokine than commercially available polyclonal antibodies (47%, 51%, and 41% inhibition, respectively).
[0166] Similarly, KU-812 cells were incubated with alkaline purified test antibodies (final concentration 100-0.01 μg / mL (approximately 667-0.067 nM)), recombinant human IL-33 (ATGen, ILC0701) (final concentration 3 ng / mL (approximately 0.15 nM)), human IL-3 (PeproTech, 200-03, final concentration 10 ng / mL (approximately 0.67 nM), and human complement C5a (Sigma-Aldrich, A mixed solution of 1 nM of C5788 (final concentration) was added and incubated at 37°C for 24 hours. The concentrations of IL-5 and IL-13 in RPMI-1640 medium containing 10% FBS were measured. In addition, the cell viability at the time of medium collection was measured using a cell counting kit, and it was confirmed that the inhibitory effect on IL-5 and IL-13 production was not due to a decrease in the number of viable cells. In this evaluation system, the alkali-purified test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) showed an inhibitory effect of 50% or more on IL-5 and IL-13 production at a final concentration of 1 μg / mL.
[0167] Example 12: Evaluation of neutralizing activity of human IL-33 in vitro using human peripheral blood mononuclear cells The in vitro neutralizing activity of the test antibody (IgG) against human IL-33 was evaluated using IL-33-dependent IFN-γ production in human peripheral blood mononuclear cells (PBMCs) as an index. A commercially available polyclonal anti-IL-33 antibody (R&D Systems, AF3625) was used as a positive control. PBMCs were prepared and seeded (2x10 5 / well) and recombinant human IL-12 (Wako Pure Chemical Industries, Ltd.) (final concentration 10 ng / mL) were added. A mixture of the test antibody and recombinant human IL-33 protein (10 ng / mL) was added and incubated at 37°C for 48 hours. Thereafter, the culture supernatant was collected and the amount of IFN-γ produced in the medium was measured using an AlfaLISA TM human IFN-γ immunoassay kit (PerkinElmer) to evaluate the neutralizing activity of IL-33. In this evaluation system, the inhibition rate when the alkaline purified antibody was applied at a final concentration of 10 μg / mL was 96.9% inhibition for A10-1C04, 97.5% inhibition for A23-1A05, 98.75% inhibition for A25-2C02, 97.9% inhibition for A25-3H04, and 98.25% inhibition for A26-1F02.
[0168] Example 13: Evaluation of the effect of human IL-33 on inflammation induced by intraperitoneal administration Intraperitoneal administration of human IL-33 to mice induced various inflammatory changes, including increases in blood IgE, IgA, and IL-5, as well as increases in neutrophils, eosinophils, and basophils, and increases in splenocytes (increases in spleen weight), and pathological changes in various mucosal organs. These changes were used as indicators to evaluate the in vivo anti-inflammatory effects of the test antibody (IgG).
[0169] Human IL-33 protein (R&D Systems, 3625-IL-010) was intraperitoneally administered at 0.4 μg / individual to male C57BL6 mice (6-8 weeks old) (Charles River Japan, Inc.) for 7 days (Day 0-Day 6). In addition, the test antibody (IgG) was intraperitoneally administered for 7 days (Day 0-Day 6). Seven days after the start of administration (Day 7), the spleen weight of the group administered PBS (indicated as "vehicle" in the figure) instead of human IL-33 protein was 76 ± 4 mg on average, while the spleen weight of the IL-33 protein-administered group was 90 ± 7 mg on average. In addition, the group that received IL-33 protein plus human control IgG (MP Biomedicals, 55908) intraperitoneally at 10 mg / kg (denoted as "mpk" in the figure) had an average spleen weight of 93 ± 4 mg, whereas the group that received IL-33 protein plus the neutral purified antibody A26-1F02 intraperitoneally at 10 mg / kg had an average spleen weight of 66 ± 3 mg.
[0170] Next, the alkaline purified antibody was subcutaneously administered once (sc, one shot) on the day before administration of human IL-33 protein (Day-1) and evaluated. Seven days after the start of administration (Day 7), the spleen weight of the group administered PBS instead of human IL-33 protein was 70 mg on average, whereas the spleen weight of the group administered IL-33 protein and the above-mentioned human control IgG subcutaneously (10 mg / kg) on average was 152 mg. In contrast, as shown in Figure 8, the spleen weights of the groups administered IL-33 protein and A25-3H04 subcutaneously (1, 3, 5, 10 mg / kg) on average were 143, 106, 109, and 78 mg, respectively, and A25-3H04 concentration-dependently suppressed the increase in spleen weight due to inflammation. In addition to the anti-inflammatory effect on spleen weight, A25-3H04 was also found to suppress serum IgA and IgE concentrations, blood neutrophil counts, basophil counts, eosinophil counts, and serum IL-5 concentration, all of which were increased by human IL-33 administration (Figure 8). These results confirmed that A25-3H04 has an inhibitory effect on in vivo inflammatory responses induced by IL-33. In addition, the blood concentrations of A25-3H04 in mice measured 7 days after the start of administration (Day 7) were 0.6, 3.7, 6.5, and 20.3 μg / ml for doses of 1, 3, 5, and 10 mg / kg, respectively.
[0171] The in vivo anti-inflammatory effects of other test antibodies (IgG) were also evaluated by subcutaneous administration (10 mg / kg) using the same protocol. As a result, as shown in Figure 9, the spleen weight in the group subcutaneously administered with human control IgG was 181 mg on average, whereas the spleen weights in the groups subcutaneously administered with each alkaline purified antibody (A10-1C04, A23-1A05, A25-2C02, A26-1F02) in addition to IL-33 protein were 82 mg, 92 mg, 100 mg, and 77 mg, respectively, indicating that the increase in spleen weight due to inflammation was suppressed. Similar to the anti-inflammatory effect on spleen weight, it was confirmed that the alkaline-purified antibodies (A10-1C04, A23-1A05, A25-2C02, A26-1F02) suppressed the serum IgA concentration, serum IgE concentration, blood neutrophil count, basophil count, and eosinophil count, which were increased by administration of human IL-33 protein (Figure 9). These results confirmed that the other test antibodies (A10-1C04, A23-1A05, A25-2C02, A26-1F02), like A25-3H04, also exhibited anti-inflammatory effects against in vivo inflammatory responses induced by IL-33.
[0172] Example 14: Evaluation of the effect on lung injury induced by intratracheal administration of human IL-33 When human IL-33 protein is administered intratracheally to mice and then bronchoalveolar lavage fluid (BALF) is collected, the total cell count, eosinophil count, and neutrophil count in the BALF increase, and hyperplasia of tracheal epithelial mucus is observed. Cytokines such as IL-4, 5, 6, and 13 are also produced in the BALF. The effect of the test antibody (IgG) on lung damage can be evaluated by administering the test antibody intraperitoneally, subcutaneously, or intravenously to this system.
[0173] Example 15: Evaluation of the effect on airway hyperresponsiveness induced by intranasal administration of human IL-33 Intranasal administration of IL-33 protein to mice subsequently induces airway hyperresponsiveness to inhaled methacholine. The effect of a test antibody (IgG) on airway hyperresponsiveness can be evaluated by administering the antibody intraperitoneally, subcutaneously, or intravenously to this evaluation system.
[0174] Example 16: Evaluation of effects on IL-33 using human IL-33 knock-in mice When mite antigen or papain was administered intranasally or intratracheally to human IL-33 knock-in mice, airway inflammation was induced, and the total cell count in BALF collected from these mice increased. It is known that airway inflammation caused by mite antigen or papain is caused by the release of IL-33 from airway epithelial cells due to the protease activity of the mite antigen or papain (Oboki et al., Proceedings of the National Academy of Sciences of the United States of America, 2010, vol. 107, p18581). By administering a test antibody (IgG) intraperitoneally, subcutaneously, or intravenously to this evaluation system, the effect of the test antibody on airway inflammation caused by proteases and the effect of the test antibody on IL-33 induced in vivo can be evaluated.
[0175] Example 17: Evaluation of the effect on inflammation in a sepsis model administered intraperitoneally with LPS Sepsis is induced in human IL-33 knock-in mice by intraperitoneal administration of LPS (Oboki et al., Proceedings of the National Academy of Sciences of the United States of America, 2010, vol. 107, p18581), and the effect of the test antibody on the subsequent mortality rate can be evaluated by administering the test antibody intraperitoneally, subcutaneously, or intravenously before LPS administration. In addition, inflammatory cytokines such as IL-6 and TNF-α are detected in high concentrations in the blood within a few hours of LPS administration, and the anti-inflammatory effect of the test antibody can be evaluated by measuring these concentrations.
[0176] Example 18: Evaluation of effects on cancer in vivo using tumor-bearing mice Mouse cancer cell lines or human cancer cell lines are orthotopic, subcutaneous or intravenous transfer of appropriate cell numbers according to each cancer cell line into mice, and human IL-33 is administered. The test antibody (IgG) is intraperitoneally, subcutaneously or intravenously administered to these mice, and after transfer of the cancer cell lines, the number of cancer cells in the primary cancer site or metastatic organs is evaluated by volume or cell number, allowing the effect of the test antibody on cancer to be evaluated.
[0177] Example 19: Evaluation of Colloidal Stability of Antibodies The colloidal stability of the test antibody (IgG) was evaluated by the presence or absence of aggregates using dynamic light scattering. Each alkali-purified antibody was concentrated to approximately 50 mg / mL using VIVASPIN or VIVASPIN TURBO (sartorius, 10,000 to 50,000 MWCO). Centrifugation was performed at 4°C, and the rotation speed and time were appropriately changed. The test antibody solution was sequentially diluted and measured using dynamic light scattering (Nikkiso, Nanotrac UPA UT-151) using 200 to 250 μL of the sample, and data was obtained in the concentration range from approximately 1 mg / mL to approximately 50 mg / mL. The particle size distribution of the antibody protein was calculated from the accumulated data for 200 seconds, and the presence or absence of aggregates was evaluated. The peak in the particle size distribution of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) at around 10 nm shifted very slightly to the higher particle size side with increasing antibody concentration, and there were no peaks with particle sizes of several tens of nm or more that were thought to be due to irreversible aggregates that were not dependent on antibody concentration. These results confirmed the good colloidal stability of the test antibodies.
[0178] To quantitatively evaluate the colloidal stability, the interaction parameter (k D) was calculated. The interaction parameter, which indicates the concentration dependence of the diffusion coefficient (inversely proportional to particle size), is an important index used in the formulation design of high-concentration protein preparations such as antibodies. It has been reported that if the value of the interaction parameter is higher than -12.4 mL / g, the interaction is a repulsive interaction, with excellent colloidal stability and low self-association (Saito et al., Pharm.Res., 2013.Vol.30 p1263). The test antibody solution dissolved in PBS (pH 7.2) was concentrated to several tens of mg / mL using an ultrafiltration membrane, and the particle size of the sample, which was serially diluted two-fold with the same solvent, was measured using a dynamic light scattering measurement device (Nanotrac UPA UT151 Nikkiso). The diffusion coefficient was calculated from the obtained particle size using the following Stokes-Einstein equation.
[0179]
number
[0180] In the above formula, D is the diffusion coefficient (cm 2 / sec), K B is the Boltzmann constant (J / K), T is the thermodynamic temperature (K), π is the circular constant, η is the viscosity of the dilution solution P (poise), and d is the particle diameter (nm). The concentration dependence of the diffusion coefficient was plotted and fitted with the following formula to obtain the interaction parameter.
[0181]
number
[0182] D is the diffusion coefficient obtained by the Stokes-Einstein equation, D0 is the diffusion coefficient at infinite dilution, and c is the concentration of the test antibody at the time of measurement (g / mL). From this equation, the interaction parameter (k D ) was calculated. As a result, A10-1C04 was found to be k D =-8.1mL / g (analysis range is 0.41-63.7mg / mL), A23-1A05 is k D=-5.6mL / g (analysis range is 0.40-61.8mg / mL), A25-2C02 is k D =-6.2mL / g (analysis range is 0.43-66.3mg / mL), A25-3H04 is k D =-7.5mL / g (analysis range is 0.34-56.5mg / mL), A26-1F02 is k D =-6.7 mL / g (analysis range: 0.35-62.7 mg / mL), and the interaction parameter of each antibody was higher than -12.4 mL / g, indicating excellent colloidal stability.
[0183] Example 20: Evaluation of Thermodynamic Stability of Antibodies The thermodynamic stability of the test antibody (IgG) was evaluated by the temperature (Tm) at which the folding of the immunoglobulin domain collapses. Protein Thermal Shift Dye (Life Technologies) was added to a test antibody solution of several tens of μg / mL according to the attached instructions, and the fluorescence intensity was measured while increasing the temperature at about 1°C / min using a real-time PCR 7500 Fast (Life Technologies). The Tm was determined by analyzing the obtained data using Protein Thermal Shift (Life Technologies). When multiple Tms were observed, the lowest temperature was designated as Tm1, Tm2, etc. As a result, when neutral purified antibodies were used, A10-1C04 had Tm = 73.9°C, A23-1A05 had Tm1 = 69.3°C, Tm2 = 77.6°C, A25-2C02 had Tm1 = 69.3°C, Tm2 = 80.3°C, A25-3H04 had Tm1 = 70.0°C, Tm2 = 76.4°C, and A26-1F02 had Tm = 74.5°C. When alkaline-purified antibodies were used, A10-1C04 had a Tm of 73.7°C, A23-1A05 had a Tm1 of 69.5°C and a Tm2 of 77.5°C, A25-2C02 had a Tm1 of 69.5°C and a Tm2 of 80.4°C, A25-3H04 had a Tm1 of 70.1°C and a Tm2 of 76.4°C, and A26-1F02 had a Tm of 74.4°C. The Tms of all of the antibodies were above 65°C, indicating good thermodynamic stability.
[0184] Example 21: Evaluation of storage stability of antibodies To evaluate the storage stability of the test antibodies (IgG), each alkali-purified antibody was dissolved in citrate buffer (50 mM citric acid, 150 mM NaCl (pH 6.3)) at a concentration of approximately 10 mg / mL and stored for 4 weeks at 40° C. To evaluate the antibody monomer purity after storage, the monomer purity was measured by gel filtration analysis (SEC) and microchip capillary SDS electrophoresis (mCE-SDS), and the antigen binding activity was measured using surface plasmon resonance.
[0185] Two columns of TSKgel G3000SWXL (Tosoh) were connected and attached to an HPLC system (Beckman System Gold, 126 solvent manager, 166 detector, 508 auto sampler) for gel filtration analysis. Separation was performed at a flow rate of 0.5 mL / min using 0.1 M phosphate buffer (pH 6.7) containing 0.1 M sodium sulfate as the mobile phase solvent, and detection was performed at UV 215 nm. Approximately 10 mg / mL of the antibody stock solution was diluted 100-fold to prepare an analytical sample, and 50 μL of the diluted solution was injected. The monomer purity obtained by gel filtration analysis is shown in Table 13. All of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) retained 90% or more of monomer purity after storage at 40°C for 4 weeks, demonstrating good storage stability.
[0186] Capillary SDS electrophoresis was performed using a Lab Chip GX II (PerkinElmer). Reduction was performed under denaturing conditions according to the manufacturer's standard protocol using the HT Protein Express Reagent (PerkinElmer) reagent kit dedicated to this instrument. 2 μL of antibody stock solution at approximately 10 mg / mL was added as the analysis sample. The reagents used for electrophoresis were added to a dedicated chip, the HT Protein Express Lab Chip, version 2 (PerkinElmer), from the above-mentioned kit, and measurements were performed using the built-in protocol HT Antibody 200 for antibody analysis. As shown in Table 13, even under denaturing and reducing conditions, all of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) retained 90% or more of monomer purity after storage at 40°C for 4 weeks, demonstrating good storage stability.
[0187] Particle size measurements were performed to investigate the presence or absence of irreversible aggregate formation independent of antibody concentration after storage. The antibody stock solution was diluted 10-fold (final concentration: approximately 1 mg / mL) with citrate buffer (50 mM citric acid, 150 mM NaCl (pH 6.3)) to obtain an analytical sample, and particle size measurements were performed using dynamic light scattering (Nikkiso, Nanotrac UPA UT-151). The measurement was performed with an accumulation time of 200 seconds. No aggregates were detected after storage at 40°C for 4 weeks for any of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02, A00-0070, A00-0036), demonstrating that antibodies with excellent storage stability were obtained.
[0188] To examine the presence or absence of antigen binding ability after storage, antigen binding activity was measured using a surface plasmon resonance device Biacore T200 (GE Healthcare). Human IL-33 protein (ATGen, ILC0701) was immobilized on a Sensor Chip CM5 (GE Healthcare) using an amine coupling kit (GE Healthcare) (immobilization amount: approximately 3000 to 6000 RU). Next, the antibody storage solution was diluted 10-fold with citrate buffer (50 mM citric acid, 150 mM NaCl (pH 6.3)), and the total protein concentration in the solution was measured using a microspectrophotometer Astragene II (Astranet) (protein concentration: approximately 1 mg / mL). The antibody solution whose total protein concentration had been measured was diluted 1000-fold with HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% (v / v) Surfactant P20 (pH 7.4)) to prepare an analyte solution. Measurements were performed at 25°C. Various analyte solutions were added for 36 seconds, and sensorgrams of the binding phase were obtained. The flow rates were 5 μL / min and 100 μL / min, and the concentrations of antibodies with antigen-binding activity were determined for the sensorgrams obtained at the two flow rates by Calibration Free Concentration Analysis using a data analysis program (GE Healthcare, Biacore T200 Evaluation Software v1.0). As a control, the antigen-binding activity of various test antibodies stored at 4°C for 4 weeks was measured in the same manner, and the proportion of antigen-binding activity of the test antibodies stored at 40°C for 4 weeks was calculated. As shown in Table 13, all of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) retained 90% or more of their antigen-binding activity after storage at 40°C for 4 weeks, demonstrating good storage stability.
[0189] [Table 13]
[0190] Example 22: Evaluation of antibody stability by forced oxidation The effect of oxidation of the test antibody (IgG) on the antigen-binding activity was examined. Hydrogen peroxide (final concentration 1%) was added to various alkali-purified antibodies at a final concentration of about 1 mg / mL, and the antibodies were oxidized at 37°C for 24 hours. Then, an 80 mM methionine solution was added to terminate the oxidation. Next, the test antibody solution was replaced with PBS using a desalting column Zebaspin (Thermo Scientific). The antigen-binding activity of the oxidized test antibody was examined using a surface plasmon resonance device Biacore T200 (GE Healthcare) in the same manner as in Example 21. When the ratio of antigen-binding activity after oxidation treatment to that of the various test antibodies not subjected to oxidation was calculated, A10-1C04 retained 83%, A23-1A05 95%, A25-2C02 100.5%, A25-3H04 98.7%, and A26-1F02 89.5% of their binding activity. These results show that all of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) showed stability, retaining more than 80% of their antigen-binding activity when subjected to forced oxidation by treatment with 1% hydrogen peroxide solution.
[0191] Example 23: Evaluation of aggregate formation due to physical stress (agitation) The test antibody (IgG) was diluted to 0.2 mg / mL with PBS and stirred in a batch cell attached to an Aggregates Sizer (Shimadzu Corporation) to apply physical stress. After moving the stir bar up and down (190 times / min) for 30 minutes at room temperature, the concentration of aggregates from 40 nm to 20 μm was measured using the Aggregates Sizer. When alkaline purified antibodies were used, the aggregate concentrations generated by stirring were 17.2 μg / mL for A10-1C04, 16.4 μg / mL for A23-1A05, 13.3 μg / mL for A25-2C02, 23.4 μg / mL for A25-3H04, and 17.0 μg / mL for A26-1F02. The aggregate formation induced by physical stress was 15% or less for all antibodies, and all test antibodies were stable against physical stress.
[0192] Example 24: Evaluation of antibody concentration in mouse blood Fluorescently labeled test antibodies (IgG) were administered intravenously (3 mg / kg) to male C57BL6 mice (8-10 weeks old) (Charles River Japan), and the concentration of the test antibodies was measured by detecting the fluorescence in the plasma. As shown in Figure 10, when alkaline purified antibodies were used, all of the test antibodies (A10-1C04, A23-1A05, A25-2C02, A25-3H04, A26-1F02) had a elimination half-life of 100 hours or more, indicating good stability in the blood.
[0193] Example 25: Evaluation of changes in blood concentration in monkeys After intravenously administering the test antibody (IgG) (1 mg / kg) to male cynomolgus monkeys (2-3 years old) (Hamley), the concentration of the test antibody in the serum was measured using a Human Therapeutic IgG1 EIA Kit (Cayman Chemical, 500910). Alkaline-purified antibody A10-1C04 was administered to two cynomolgus monkeys (No. 201, 202), and alkaline-purified anti-A23-1A05 was administered to one cynomolgus monkey (No. 301). As shown in Figure 11, the elimination half-life of A10-1C04 was 16.56 days (No. 201) and 11.40 days (No. 202), and the clearance values were 3.598 mL / day / kg (No. 201) and 5.451 mL / day / kg (No. 202). The elimination half-life of A23-1A05 was 10.87 days, and the clearance value was 10.07 mL / day / kg. All of the test antibodies showed good stability in the blood of cynomolgus monkeys.
[0194] Example 26: Immunogenicity evaluation of antibodies An in vitro T cell assay was performed to evaluate the immunogenicity of the test antibody (IgG) (Lonza). To represent the target population, 50 donors were used. Dendritic cells derived from human peripheral blood collected from the donors were supplemented with 50 μg / mL of various alkaline purified antibodies and allowed to incorporate into the dendritic cells. Meanwhile, CD4-positive T cells were isolated from human peripheral blood collected from the same donor. Then, both, i.e., the dendritic cells incorporating the test antibody, were co-cultured with CD4-positive T cells, and the response (proliferation) of the CD4-positive T cells was measured. The immunogenicity risk when the antibody was administered to humans was evaluated by comparing the response of CD4-positive T cells obtained by carrying out the same experiment using a buffer (PBS) that did not contain the test antibody as a negative control. As a result, no difference in T cell response was observed between the negative control and any of the test antibodies (A10-1C04, A25-2C02, A25-3H04, A26-1F02).
[0195] Example 27: Evaluation of human tissue cross-reactivity The cross-reactivity of the test antibody (IgG) to human tissues (frozen sections of 35 tissues from one donor that meet FDA and EMA guidelines) was evaluated by immunohistochemical staining (Covance Laboratories Ltd.). The 35 tissues included adrenal gland, bladder, blood cells, bone marrow, mammary gland, cerebellum, cerebral cortex, colon, endothelial cells (blood vessels), eyeball, fallopian tube, gastrointestinal tract (including smooth muscle), heart, kidney (glomerulus, tubule), liver, lung, lymph node, ovary, pancreas, parathyroid gland, parotid gland, peripheral nerve, pituitary gland, placenta, prostate, skin, spinal cord, spleen, striated muscle, testis, thymus, thyroid gland, tonsil, ureter, and uterus (cervix, endometrium). As a result, when alkaline purified antibodies were used, strong staining was confirmed in vascular endothelial cells (positive control), where IL-33 expression is widely known, for all the tested antibodies (A10-1C04, A23-1A05, A26-1F02, A25-2C02). In addition, cross-reactivity to the cytoplasm or nucleus was confirmed in various tissues such as epithelial cells, interstitial cells, nerve tissue, muscle tissue, and blood cells, but cross-reactivity to the cell membrane was not observed in any tissue. According to the ICH S6(R1) guideline and other papers (Toxicologic Pathology 2010, 38(7):1138-1166), cross-reactivity to the cytoplasm or nucleus, which are unlikely to be reached by antibodies in vivo, is considered to have little toxicological significance. Therefore, no toxicity concerns were found for any of the tested antibodies (A10-1C04, A23-1A05, A26-1F02, A25-2C02).
[0196] Example 28: Narrowing of epitope regions of A10-1C04 and A25-3H04 The anti-IL-33 monoclonal antibodies A10-1C04 and A25-3H04 bound to the PEP14 epitope described in Example 1 above. For shorter continuous amino acid sequences contained in PEP14 consisting of 20 amino acid residues, two types of epitopes (LEDESYEIYV (SEQ ID NO: 426 in the Sequence Listing) and EDESYEIYV (SEQ ID NO: 427 in the Sequence Listing)) were found by experiments using a phage display library that displays such amino acid sequences. Peptide LEDESYEIYV corresponds to residues 138 to 147 of human IL-33 shown in SEQ ID NO: 226 in the Sequence Listing, and peptide EDESYEIYV corresponds to residues 139 to 147 of human IL-33 shown in SEQ ID NO: 226 in the Sequence Listing. These peptides were synthesized, and the affinity with the alkaline-purified antibody was examined by KinExA experiments similar to those in Example 9. d The calculations were as follows (Table 14).
[0197] [Table 14] [Industrial Applicability]
[0198] The neutralizing antibody of the present invention can be used as a pharmaceutical composition for the diagnosis, treatment, prevention, or alleviation of IL-33-related diseases.
Claims
1. An IL-33 neutralizing monoclonal antibody that binds to an epitope consisting of an amino acid sequence containing at least six amino acid residues selected from the amino acid residues of an aspartic acid residue at position 131, a glutamine residue at position 132, a serine residue at position 133, a threonine residue at position 135, an alanine residue at position 137, a leucine residue at position 138, a glutamic acid residue at position 139, a serine residue at position 142, a tyrosine residue at position 143, a glutamic acid residue at position 144, an isoleucine residue at position 145, a tyrosine residue at position 146, a glutamic acid residue at position 148, an aspartic acid residue at position 149, and a leucine residue at position 150 of SEQ ID NO:226 in the Sequence Listing.
2. The IL-33 neutralizing monoclonal antibody according to claim 1, wherein the epitope is an epitope consisting of an amino acid sequence containing at least six amino acid residues selected from the amino acid residues consisting of a leucine residue at position 138, a glutamic acid residue at position 139, a serine residue at position 142, a tyrosine residue at position 143, a glutamic acid residue at position 144, an isoleucine residue at position 145, and a tyrosine residue at position 146.
3. The IL-33 neutralizing monoclonal antibody comprises a CDR set as set forth in Table 1 below: 【Table 1】 The IL-33 neutralizing monoclonal antibody according to claim 1 or 2, comprising:
4. The IL-33 neutralizing monoclonal antibody according to any one of claims 1 to 3, wherein the IL-33 neutralizing monoclonal antibody is A10-1C04 or A25-3H04.
5. The antibody according to any one of claims 1 to 4, wherein the antibody is a chimeric antibody, a humanized antibody or a human antibody.
6. The antibody according to claim 5, wherein the amino acid sequence of the framework region is the amino acid sequence of a human germline framework region or a combination thereof.
7. A pharmaceutical composition for treating, preventing, or alleviating an IL-33-associated disease, comprising the antibody according to any one of claims 1 to 6.
8. The pharmaceutical composition according to claim 7, wherein the IL-33-associated disease is selected from the group consisting of asthma, atopic dermatitis, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), Crohn's disease, ulcerative colitis, arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, scleroderma, ankylosing spondylitis, hepatic fibrosis (including primary biliary cirrhosis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute kidney injury, vasculitis, and cancer.
9. A cytokine expression inhibitor comprising the antibody according to any one of claims 1 to 6.
10. The cytokine expression inhibitor according to claim 9, which suppresses the expression of TNF-α, IFN-γ, IL-1β, IL-4, IL-5, IL-6 or IL-13.
Citation Information
Patent Citations
Use of interleukin-33 (il33) and the il-33 receptor complex
JP2007523089A
Fully human monoclonal antibody against il-13
JP2008520684A
IL-1β-conjugated antibody and its fragments
JP2008543340A
Anti-human interleukin-20 antibody
JP2011526591A
Human anti-IL-33 neutralizing monoclonal antibody
JP2022191486A
